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ABSTRACT 
The majority of HIV-1 infections around the world occur via sexual intercourse and 
women, especially in developing countries, are disproportionately affected. Recently a 
number of strategies have been proposed to control the spread of HIV, among these the 
use of microbicides to prevent the sexual transmission of the virus. A clinical trial of 1% 
tenofovir gel that conferred up to 39% protection provided a proof-of-concept that an 
anti-HIV microbicide is feasible. Various other compounds, acting at different stages of 
HIV-1 life cycle, are also being investigated as potential microbicides. These include the 
lectins Griffithsin (GRFT), cyanovirin-N (CV-N) and scytovirin (SVN). GRFT was 
isolated from the red algae griffithsia sp. while CV-N and SVN were isolated from the 
blue green alga Nostoc ellipsosporum and the cyanobacterium Scytonema varium, 
respectively. These lectins bind mannose-rich glycans found on the surface of HIV-1 
envelope and act as entry inhibitors. Although HIV-1 subtype C is the main cause of 
infections around the world, almost all studies conducted with GRFT, CV-N and SVN 
are based on subtype B viruses. The Chapter Two sought to establish the neutralization 
sensitivity of HIV-1 subtype C viruses to the three lectins, using both a cell line and 
primary cells, and compared this sensitivity to subtype B. This Chapter also examined 
mannose-rich glycans on HIV-1 that are involved in GRFT, CV-N and SVN binding. The 
conclusion from this study was that the neutralization of subtype C viruses by these 
lectins is similar to subtype B and that the 234 and 295 mannose-rich glycans were 
involved in their interaction with the virus. In general these data supported further studies 
on the use of GRFT, CV-N and SVN for prevention of HIV-1 subtype C sexual 
transmission. In Chapter Three, the ability of GRFT to expose the CD4 binding site 
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(CD4bs) on HIV-1 gp120 is explored. I found that this exposure resulted in the 
enhancement of HIV-1 binding to plates coated with anti-CD4bs antibodies b12 and b6 
or the CD4 receptor mimetic CD4-IgG2. This lectin also synergized with b12 and HIV-
positive plasma containing antibodies to the CD4bs to neutralize the virus. Furthermore, 
the glycan at position 386, which shields the CD4bs, was shown to be involved in both 
GRFT enhancement of HIV-1 binding to b12 and b6 and in the synergistic interaction 
between the lectin and these antibodies. The importance of this study is that it 
investigated in details the effect of GRFT binding on HIV-1 envelope and also suggests 
this lectin can be used in combination with anti-HIV-1 antibodies to synergistically 
enhance the anti-viral activity. In Chapter Four I investigated GRFT, CV-N and SVN 
inhibition of the virus binding to the DC-SIGN receptor and their inhibition of the DC-
SIGN transfer of HIV-1 to target cells. These lectins only moderately inhibited the virus 
binding to the receptor while they potently inhibited its transfer to target cells. However, 
the inhibition of transfer was stronger when the virus bound the lectins after binding the 
DC-SIGN receptor compared to when it bound the lectins prior to binding the receptor. 
These three lectins can, therefore, inhibit the sexual transmission of HIV-1 since the DC-
SIGN-mediated transfer of the virus to susceptible cells is pivotal to this mode of 
transmission. Chapter Five is an investigation of the ability of HIV-1 subtype C to escape 
GRFT, CV-N and SVN, which involved growing the virus under escalating 
concentrations of these compounds. This was to know how this virus behaves under 
conditions of continuous exposure to the lectins. I found that HIV-1 subtype C became 
increasingly resistant to the lectins and viral envelope sequence analysis showed that this 
was associated with the deletion of mannose-rich glycans on gp120. Furthermore, of the 
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11 potential mannose-rich glycosylation sites on gp120 seven (230, 234, 241, 289, 339, 
392 and 448) were involved in GRFT, CV-N and SVN resistance. Thus, the conclusion 
was that although these three lectins are potent inhibitors of HIV-1 infection, the virus is 
also able to escape their neutralization by deleting mannose-rich glycans on its envelope. 
However, the fact that escape to these lectins involved multiple deglycosylation and was 
only partial suggests that HIV-1 subtype C escape from GRFT, CV-N and SVN in a 
microbicide formulation may not be an easy process. We discuss the implications of these 
findings in Chapter Six and suggest future studies that could complement data presented 
in this thesis. Overall our data show that GRFT, CV-N and SVN can prevent the sexual 
transmission of both free and DC-SIGN associated HIV-1 particles and supports further 
development of these lectins as microbicides against HIV-1. 
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CHAPTER 1 
INTRODUCTION 
 
 
 
 
 
 
  
 2 
1.1. Background 
 
According to the 2009 World Health Organization report on the global AIDS 
epidemic there were 33 million people living with HIV in 2008 
(http://www.unaids.org).  The same report estimated the number of new HIV 
infections to be 2.7 million during the same year with the overall AIDS death rate 
reaching 2 million. HIV is mainly transmitted through sexual intercourse that 
accounts for ~ 80% of infections around the world (http://www.unaids.org). 
 
   
Figure 1.1: The estimated number of people living with HIV/AIDS in 2008 by 
region. The geographic distribution of the world population living with HIV (adult 
and children combined) as published by the World Health Organization report on 
global AIDS (http://www.unaids.org). 
 
Globally sub-Saharan Africa remains the most affected region (Figure 1.1) 
with an estimated 22.4 million people infected with HIV. In 2008 ~ 75% of all deaths 
 3 
caused by the virus occurred in this region. However, the HIV epidemic is most 
severe in Southern Africa with a prevalence ranging from 10-28% in the adult 
population (Figure 1.2). 
   
Figure 1.2: HIV mortality and prevalence in Africa. Geographic distribution of 
HIV prevalence in the adult population in Africa published in 2007. Warmer colour 
indicate higher prevalent of the virus (http://www.unaids.org). 
 
Compared to men, women are more affected by the HIV epidemic and this is 
more pronounced in Sub-Saharan Africa where women constitute ~ 60% of all cases 
of HIV infection (83). Furthermore, the proportion of females infected with HIV 
compared to males is higher in the 15 to 24 years old age category as a study 
conducted in a number of Sub-Saharan African countries revealed (Figure 1.3).  
The discovery of an effective vaccine against HIV-1 remains the main focus of 
HIV prevention strategies (94). However, the genetic diversity of HIV poses a serious 
challenge to this effort which is exacerbated by the fact that the correlates of 
protection for an effective HIV-1 vaccine are unknown (49, 73, 94). Due to this, many 
compounds with the ability to block HIV-1 entry and replication in target cells are 
being proposed as potential microbicides to prevent the sexual transmission of HIV. 
Amongst HIV-1 microbicide candidates are found non-specific inhibitors such as 
 4 
buffering agents that inactivate viruses by maintaining the acidic pH in the vaginal 
tract; moderately specific inhibitors such as anionic polymers that neutralize the virus 
by binding to its positively charged envelope glycoproteins; antiretroviral agents such 
as tenofovir that target HIV-1 reverse transcriptase (39); and lectins such as griffithsin 
(GRFT), cyanovirin-N (CV-N) and scytovirin (SVN) that bind to HIV-1 envelope to 
inhibit its entry into target cells (17, 22, 103).  
  
Figure 1.3: Comparison of HIV prevalence between males and females in the 15 
to 24 years old age category. Young females were found to be disproportionately 
more infected by HIV than young males in all 20 countries selected for the study 
except the Democratic Republic of Congo and India (http://www.unaids.org). 
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1.2. HIV structure, genetic diversity and life cycle  
HIV belongs to the genus lentivirus and family Retroviridae (76). A mature HIV 
particle is made of an outer lipid bilayer (envelope) (Figure 1.4) that is derived from 
the host cell during the budding step of the viral life cycle (64). Protruding outside the 
envelope is the gp41-gp120 glycoprotein complex that occurs as both trimer and 
monomer on the viral surface (101, 121, 160, 164). The interaction between the trans-
membrane gp41 and gp120 is non-covalent. An HIV particle contains a core 
consisting of the p24 protein (64). Inside the core are found the viral enzymes 
protease, reverse transcriptase and integrase that are essential for HIV replication and 
the two RNA molecules that constitute the viral genome. The core is separated from 
the envelope by a matrix made of the p17 protein.  
   
  
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Structural arrangement of an HIV particle. An idealized computer 
generated structure of an HIV particle. In maroon is the outer lipid bilayer that 
constitutes the viral envelope. All other major components of the virus are indicated 
in the Figure (http://www.washington.edu/.../columns/dec00/cells.4.htm).  
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HIV is classified as HIV type 1 (HIV-1) and HIV type 2 (HIV-2) (93). HIV-1 was 
isolated in 1983 and is responsible for the global pandemic while HIV-2, discovered 
two years later, is less pathogenic and less transmissible. This virus is mainly limited 
to West Africa (76).  
HIV-1 is divided into groups named group M, O, and N (25, 26). The group M 
is further divided into subtypes also known as clades. These subtypes are referred to 
alphabetically as A, B, C, D, F, G, H, J and K (25, 76). Subtype A and F are in turn 
divided into sub-subtype A1 and A2 and sub-subtype F1 and F2, respectively (26). 
Recombinant viruses, made from the recombination of genomes from different 
subtypes, also form part of group M viruses and they are more common in regions 
where there are different subtypes in circulation (26). 
The high genetic diversity displayed by HIV-1 is partly attributed to its error 
prone reverse transcriptase enzyme (64). More precisely this enzyme introduces one 
error per genome with every round of replication. In addition to the high replication 
rate and the frequent recombination events between different viral genomes, the host 
immune pressure also plays an important role in HIV-1 diversity. 
The global HIV-1 epidemic is characterized by a disproportionately high 
prevalence of a given subtype or recombinant virus in a particular region. For 
example HIV-1 infection in the North and Central America is mainly caused by 
subtype B viruses (Figure 1.5). This subtype is also the most prevalent in Western 
Europe. However, in Southern Africa HIV-1 infection is mainly caused by the 
subtype C virus that is also responsible for over 50% of HIV infections around the 
world (26). 
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Figure 1.5: The global HIV-1 prevalence by subtype. The Figure shows the spread 
of HIV-1 subtypes around the world. Each subtype is colour coded and the countries 
where it is found are indicated. This Figure was taken from the website 
(http://img.medscape.com/article/708/915/708915-fig1.jpg). 
 
The HIV-1 life cycle begins with the adsorption of the viral particle onto the 
surface of a target cell via the interaction of gp120 and the CD4 receptor (63). 
However, the CD4 receptor promoted infection requires the presence of a co-receptor 
which is, most commonly, the CCR5 chemokine receptor although the CXCR4 
chemokine receptor is also used (65). HIV-1 that use the CCR5 co-receptor are 
referred to as R5 viruses and those that use the CXCR4 co-receptor are referred to as 
X4 viruses (136). The binding of the virus to the CD4 receptor results in a major 
conformational change of the gp41-gp120 trimer that exposes the co-receptor binding 
site (88). This is followed by the fusion of the viral envelope and the cell membrane 
(63), a process mediated by gp41 (56). After the cell-virus fusion, the viral genomic 
RNA is released into the cellular cytoplasm where HIV-1 reverse transcriptase 
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mediates its conversion into cDNA that later translocates to the nucleus to integrate 
into the host cell chromosome as proviral DNA. This process is mediated by the viral 
enzyme integrase (64).  Subsequent to the integration step is the transcription of the 
integrated viral DNA to synthesize RNA and proteins. The latter (protease, integrase 
and reverse transcriptase) are further processed to their final active form by HIV-1 
protease (65). The synthesized RNA and proteins are then packaged into new viral 
particles that bud from the cell to infect other cells.       
 
1.3.  HIV-1 gp120-gp41 glycoprotein complex 
1.3.1.  Native structure  
HIV-1 has evolved from chimpanzees simian immunodeficiency virus (SIV) (135) 
and both viruses still share many essential genotypic and phenotypic characteristics 
(34). Thus much of what we know about the structure of HIV-1 gp41-gp120 complex 
(Env) is derived from studies conducted with SIV Env.  
The structure of SIV and HIV native Env (gp41-gp120 trimer) has been 
visualized by three research groups using cryoelectron tomography. Zhu et al. (164) 
proposed that the SIV gp41-gp120 trimer is made of a gp120 ‘head’, comprising the 
three gp120 units, attached to three transmebrane gp41 proteins projecting outward 
like “tripod legs”. In this structure the head is made of a primary mass and two 
secondary lobes while the visible part of the leg is composed mainly of the membrane 
proximal external region (MPER) of gp41 located between the membrane spanning 
domain (MSD) and the C-terminal heptad repeat 2 (HR2) of the glycoprotein. In the 
same study Zhu et al. also reported that HIV-1 Env spikes are not evenly spread on 
the viral surface. Instead, they form clusters in which protein complexes are separated 
from their nearest neighbour by ~15 nm (Figure 1.6). In addition, Zhu et al. studied 
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the structure of HIV-1 native Env using the same technique they used for SIV (165) 
which revealed that HIV-1 Env was also made of a ‘head’ attached to tripod-like legs. 
 
 
 
             a)                   b) 
                                                   
 
Figure 1.6: The distribution of gp41-gp120 trimers on HIV-1 envelope. Top (a) 
and bottom (b) views of an HIV-1 particle showing clusters of Env circled in red. This 
Figure is an adaptation from Zhu et al. (164).  
 
Contrary this, Zanetti et al. showed that the native SIV Env is made of a three lobbed 
‘head’, constituting the gp120 trimer, attached to three tightly packed gp41 monomers 
resulting in a lolly pop-like structure (160).                              
However, Liu et al. proposed a native Env structure that was markedly 
different from those of the two previous groups (88). One of the most striking 
differences in this structure was the distinctive hole in the gp120-gp120 interface 
(Figure 1.7). However, the gp41 arrangement of this structure bore similarities to that 
of Zanetti et al. The Liu et al. model is now widely believed to be the correct 
envelope trimer structure.   
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     a)                                                                     b) 
                                    
Figure 1.7: Cryo-electron tomography structure of HIV-1 native Env proposed 
by Liu et al. (a) and (b) side views of HIV-1 gp41-gp120 trimer taken from two 
different angles. The arrow in (b) shows the location of gp41. This Figure is an 
adaptation from Liu et al. (88).   
 
1.3.2. HIV-1 Env glycosylation  
HIV-1 gp41 and gp120 are encoded by the Env gene in the viral genome (65) and are 
synthesized in the rough endoplasmic reticulum as a single molecule that then 
undergoes extensive glycosylation with N-linked glycans to form gp160 (51). This is 
followed by gp160 oligomerization i.e. assembly into a gp41-gp120 trimer. All N-
linked glycans on gp160 are initially mannose-rich before being either fully processed 
to form complex glycans or partially processed to form hybrid glycans (Figure 1.8). 
This processing takes place in the Golgi-apparatus. Mannose-rich glycans are made of 
a stretch of 7 to 9 terminal mannose residues, complex glycans contain terminal sialic 
acid residues while hybrid glycans are a mixture of both (30, 85). Once the gp160 
trimer is cleaved into gp41 and gp120, by the host cell proteases (43, 67), it is 
exposed on the cell membrane from which the virus derives its envelope during the 
budding process.  
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Figure 1.8: A diagram of the processing of HIV-1 gp160 N-linked glycans. The 
processing of N-linked glycans on gp160 begins with mannose-rich glycans shown on 
the top left of the Figure and ends with complex glycans show at the bottom left. Glc, 
Man, SA, GlcNAc, Gal, fuc and Asn stand for glucose, mannose, sialic acid, N-
acetyl-glycosamine, galactose, fucose and asparagine, respectively. This Figure was 
taken from an article by Balzarini (6). 
 
 
Glycans on HIV-1 gp120 account for ~50% of its molecular mass (82, 85) 
(Figure 1.9). However, while mannose-rich and hybrid glycans are found exclusively 
in the conserved regions of this glycoprotein, complex glycans are located in its 
variable regions. On average there are ~24 potential N-linked glycosylation sites on 
gp120. Complex oligosaccharides are found on 13 of these sites and the remaining 11 
are occupied by hybrid and/or mannose-rich glycans (85, 166). Although Leonard and 
co-workers reported that all these sites are glycosylated, a study by Go et al. 
suggested that this is not always the case (58, 85). This being said, it is important to 
note that recently Doores et al. reported that 98% of glycans on native HIV-1 
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envelope (Env) are barely processed beyond Man5GlcNAc2 i.e. five mannose residue 
glycans (48).   
                     
Figure 1.9:  N-linked glycans on HIV-1 gp120. N-linked glycans on the surface of 
gp120 are shown in cyan, red and green and their positions are based on HIV-1 
viruses HXBc2 and YU2. This Figure was taken from Kwong et al. (80).  
 
Glycans on HIV-1 envelope play an important role in mediating the virus 
interaction with key cellular receptors such as the DC-SIGN receptor (57, 119, 120). 
This receptor, expressed on dendritic cells, enables the virus to be transported from 
the sites of mucosal transmission to the lymph nodes to infect CD4+ T cells (117, 
120). In addition, HIV-1 glycans promote the proper folding of the virus 
glycoproteins (86), determine the virus antigenicity and sensitivity to envelope 
inhibitors as well as enable the virus to develop resistance to neutralizing antibodies 
(16, 59, 155).   However, HIV-1 glycosylation patterns vary between subtypes as can 
be seen by comparing viruses from subtypes A, B and C (161). For example, 75% of 
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subtype A and B envelopes are glycosylated at position 295 while only 20% of 
subtype C are glycosylated at this site (Figure 1.10); and at position 230 there are 5% 
of subtype A and 20% of subtype B that are glycosylated compared to over 80% of 
glycosylation for subtype C. Furthermore, at position 289 less than 10% of subtype A 
are glycosylated and also almost none of these viruses is glycosylated at position 392. 
However, for both subtype B and C the level of glycosylation at positions 289 and 
392 is above 65%.   
 
Figure 1.10: HIV-1 subtype A, B and C mannose-rich glycosylation pattern. This 
Figure is an adaptation from Zhang et al. (161). The position of mannose-rich glycans 
is the same as published by Leonard et al. (85). 
 
1.3.3. Molecular structure of HIV-1 gp120 
Generally speaking HIV-1 gp120 is made of four faces which are: the variable face 
composed of variable regions; the non-neutralizing face that is mainly located at the 
gp120 interface of the Env trimer; the heavily glycosylated silent face and the 
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neutralizing face that includes the receptor binding site and the region exposed to 
neutralizing antibodies (Figure 1.11a and b) (79).    
            
                  a) 
                                      
                 b) 
                              
 
Figure 1.11: Spacial arrangement of the four HIV-1 gp120 faces. (a) The positions 
of the four variable loops that constitute the variable face are shown. The Figure does 
not show the variable loop 1; however, it is in close vicinity of the variable loop 2 (see 
Figure 1.12 and 1.13). The positions occupied by N-linked glycans are shown in blue. 
(b) The non-neutralizing face (maroon), the silent face (yellow) and the neutralizing 
face (green) of gp120. This Figure is an adaptation of Wyatt and Sodroski (157).   
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HIV-1 gp120 has five variable regions or loops made of amino acid sequences 
that are highly variable between subtypes (Figure 1.12) (85, 92). The arrangement of 
these regions is such that adjacent variable loops are separated by a conserved region, 
made of relatively conserved amino acid sequences and there are five conserved 
regions on gp120. The five variable loops are exposed on the outside of gp120 while 
the conserved regions are protected by folding inside the glycoprotein (157). Together 
with the glycosylation of gp120, this special arrangement of variable and conserved 
regions protects the virus from the host immune pressure. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: HIV-1 gp120 amino acid sequence and linear arrangement of 
variable and conserved regions. Two-dimensional structure of HIV-1 gp120; the 
small numbers stand for the positions of the numbered amino acids according to the 
sequence of HIV-1 HXB2. The C stands for constant region and the V stands for 
variable region. The location of mannose-rich glycans is indicated by tri-branched 
antennae and that of complex glycans by U-shaped antennae. This Figure was adapted 
from McCaffrey et al. (92).   
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However, besides its division into the variable, non-neutralizing, neutralizing 
and silent face, HIV-1 gp120 can also be seen as a two domains glycoprotein and 
these domains are the outer domain, in which are found most of gp120 glycans, and 
the less glycosylated inner domain (Figure 1.13) (163). Between these two domains is 
found a sheet of four anti-parallel β-strands known as the bridging sheet. In the gp41-
gp120 complex the inner domain is sandwiched between gp41 and the outer domain 
(88). The crystal structure of HIV-1 gp120, in complex with a two-domain fragment 
of the human CD4 receptor and the Fab fragment of the CD4 induced epitope 
antibody 17b, showed that the inner domain is made of seven β-strands and two α 
helixes while the outer domain is made of two barrels, the termini distal barrel 
containing seven anti-parallel β-strands and the proximal barrel made of six mixed-
directional β-strands surrounding an α helix (Figure 1.13) (81). The two barrels are 
connected by a barrel-barrel juncture.  
 
 
 
Figure 1.13: The ribbon structure of HIV-1 gp120. (a) The Figure shows the 
structural arrangement of the major components of gp120 with numbered strands and 
the positions of the variable loops indicated. This Figure is an adaptation from Kwong 
et al. and Zhou et al. (81, 163).  
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1.3.4. The CD4 and co-receptor binding sites 
The CD4 receptor is the main receptor used by HIV-1 to infect cells (81, 157). Its 
binding site is made of a discontinuous region located on the outer surface of gp120 
comprising conserved amino acid sequences shielded from the immune pressure by 
variable loops (28). More precisely, the CD4 receptor binds gp120 at a site between 
the inner domain, the outer domain and the bridging sheet (Figure 1.14) 
(http://www.hiv.lanl.gov/content/immunology/pdf/1998/REVIEWS/sodroski.pdf). 
The gp120-CD4 interface has two cavities: a shallow cavity occupied by water 
molecules and a deep cavity extending 10 Å inside gp120 (157). The opening of the 
deep cavity is occupied by the CD4 residue Phe43 that has been shown to be critical 
for gp120-CD4 interaction. However, Asp368 of gp120 that interacts with Arg59 of 
CD4 together with other gp120 residues, important for CD4 binding, are also found 
around this cavity.  
 
                       
Figure 1.14: The CD4 receptor binding site on gp120. The red patches show the 
CD4 binding site while the green patches show the CCR5 co-receptor binding site on 
gp120. This Figure was taken from Wyatt et al. 
(http://www.hiv.lanl.gov/content/immunology/pdf/1998/REVIEWS/sodroski.pdf). 
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Studying the crystal structure of SIV gp120, Chen et al. (34) showed that in 
both unliganded and CD4 bound state the outer domain has essentially the same 
structure. However, upon CD4 binding major changes take place in the inner domain 
that involve a four-turn α helix, a β ribbon, a three-stranded β sheet and a α-helix at 
the outer-domain/inner-domain junction (Figure 1.15). The CD4 receptor binding to 
gp120 also induces the formation of the four-strand bridging sheet located between 
the outer and inner domain.  
 
 
Figure 1.15: Change of conformation induced in SIV gp120 upon the CD4 
receptor binding. SIV gp120 in its unliganded conformation is shown on the left 
hand side and the CD4 bound conformation is shown on the right hand side (34). 
 
 
Besides being shielded by variable loops, access to the CD4 binding site is 
also impaired by conformational masking of this site; an effect caused by the size of 
the antibody foot print on gp120, the orientation of the antibody-gp120 bonds 
imposed by Env glycans and the required change in the gp120 conformation upon 
antibody binding (79). These factors combine to make the change in entropy of 
certain antibody-CD4 binding site interaction largely negative. Here it should be 
noted that the more negative the entropy of a reaction the less it is thermodynamically 
favoured or likely to occur (52). Using isothermal titration calorimetry, Kwong et al. 
showed that antibodies that bind to the receptor-binding-site epitope had large 
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negative entropies compared to antibodies that didn’t bind to this site (79). Their 
study also showed that the binding of the CD4 receptor to gp120 has large negative 
entropy. However, Kwong et al. suggested that the simultaneous binding of CD4 
receptors to gp120 in the same or different Env trimers provides sufficient avidity to 
overcome the conformational masking (79).  
 
1.3.5. The co-receptor binding site 
HIV-1 use of either the CCR5 or CXCR4 co-receptor is a major determinant of viral 
pathogenesis and disease progression (100). Most HIV-1 infections begin with viruses 
that utilise the CCR5 co-receptor and in many cases the emergence of strains that use 
the CXCR4 co-receptor occurs in later stages of the disease (100). The bridging sheet 
and the V3 loop in gp120 constitute the co-receptor binding site (Figure 1.14 shows 
the CCR5 binding site which overlaps the CXCR4 binding site) (157) and signature 
amino acids sequences in the V3 loop determine the co-receptor specificity (100, 
125).  
  
1.4. HIV-1 sexual transmission  
1.4.1. The female genital tract  
The female genital tract comprises the vaginal tract and the cervix. This genital tract 
is covered by a stratified squamous epithelial cell lining starting in the vagina and 
ending at the ectocervix (Figure 1.16) (38, 136). This lining is divided into five zones 
namely; the cornified, the condensation, the clear, the parabasal and the basal zone 
(Figure 1.17). However, the epithelial cell lining in the endocervical canal only has 
one layer, a structure that makes it more vulnerable to disruptions such as those 
caused by sexual intercourse induced microtrauma (99).  
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Figure 1.16: Female genital tract anatomy. A cross section of the female genital 
tract showing the vagina and the cervix composed of the endocervical canal and the 
ectocervix. This Figure was adapted from Coombs et al. (38).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.17: The composition of the vaginal and cervical squamous epithelial cell 
lining. The stratified structure of the squamous epithelial cell lining showing its five 
layers; the lipoidal material and dermosomes found between its constituent cells are 
also shown.  This Figure was taken from Shattock and Moore (136).  
 
 
Many HIV-1 target cells are found in both the vagina and the cervix. For 
example CD4+ mononuclear lymphocytes and inflammatory cells are present in the 
stroma of the cervix (38) while Langerhans cells (LCs), that play an important role in 
mediating HIV-1 crossing of the vaginal mucosa, are located inside the epithelial cell 
lining. However, it should also be noted that recent reports suggested that LCs 
interaction with HIV may block its transmission (41). Lastly, the subepithelium and 
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the lamina propria contain a significant population of macrophages, CD4+ T cells and 
dendritic cells that promote HIV-1 infection (83, 99, 136).  
 
1.4.2. HIV-1 infection via the genital tract 
In females HIV-1 infection by heterosexual intercourse begins when viral particles, 
free or cell associated, released into the genital tract infect their target cells (83, 139). 
Although the precise location of HIV-1 infection in the female genital tract has yet to 
be pinpointed, cervical ectopy, caused by damage in the epithelial cell lining, has been 
associated with increased risk of HIV-1 infection (98). However, Kell et al. reported 
HIV-1 infection of a woman suffering from the Meyer-Rokitansky-Küster-Hauser 
syndrome, a congenital disorder that results in the lack of a uterus (74). This was 
supported by Miller et al. who showed that the inoculation of cell-free SIV into the 
vaginal tract of rhesus macaques resulted in a systemic infection (97). These reports 
suggest that HIV-1 can be transmitted via both the cervix and the vagina.    
Different mechanisms have been proposed to explain how HIV-1 released in 
the vaginal tract crosses the epithelial cell lining to infect cells in the lamina propria 
and subepithelium. Amongst these mechanisms, the breach of the genital mucosa 
during sexual penetration is widely accepted to be one of the main causes of male to 
female transmission of HIV-1 (38, 99, 136). The loss of the genital mucosa integrity 
can result in viral particles crossing the epithelial cell lining to infect CD4+ T cells 
and macrophages in the lamina propria and subepithelium (83, 147) (Figure 1.18). In 
fact it has been suggested that the breach of the epithelial cell lining integrity exposes 
intraepithelial LCs to HIV-1, though it has to be noted that these cells can also get 
into contact with the virus through their dendritic processes that are exposed in the 
vaginal lumen (99). Infected LCs leave their initial site of exposure to disseminate the 
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virus to other sites such lymph nodes. This is supported by a study in macaques that 
showed SIV to interact with dendritic processes of LCs in the epithelial cell lining 
enabling it to cross this barrier (137). It is also believed that the breach of the 
epithelial cell lining integrity allows viral particles to interact with dendritic cells in 
the subepithelium an interaction that also promotes their dissemination (116, 119, 
120). However, besides the sexual intercourse induced vaginal epithelial microtrauma 
that is present in > 60% of all cases of consensual sex (109), pre-existing infection of 
the genital tract caused by bacteria and viruses can also enhance the risk of 
contracting HIV-1 due to lesions and inflammation they cause (37, 38, 134). In 
addition, direct infection of epithelial cells and transcytosis have been proposed as 
mechanisms that facilitate HIV-1 crossing of the vaginal mucosa (136). However, 
some studies have demonstrated that primary cervical and vaginal epithelial cells do 
not transcytose infectious HIV-1 particles and that they also do not get infected by the 
virus (44, 62). 
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Figure 1.18: Mechanisms that facilitate HIV-1 crossing of the cervico-vaginal 
epithelial cell lining. On the left hand side of the Figure are shown mechanisms that 
facilitate the crossing of the columnar epithelium, (a) HIV-1 infection of epithelial 
cells; (b) HIV-1 transcytosis through these cells and (c) transmigration of infected 
cells between epithelial cells. On the right hand side are shown mechanism that 
promote the crossing of the stratified epithelial cell lining; (d) and (e) are steps 
involved in the physical abrasion promoted HIV-1 crossing of the vaginal mucosa. 
This Figure was taken from Shattock and Moore (136). 
 
1.4.3. HIV-1 interaction with the DC-SIGN receptor 
The DC-SIGN receptor is a C-type lectin, Ca2+ dependent, receptor that may play a 
critical role during both heterosexual and male to male transmission of HIV-1  by 
mediating the virus adsorption to dendritic cells (DCs), macrophages and endothelial 
cells (13, 21, 100, 117, 119, 136). The DC-SIGN receptor is a tetrameric type II 
transmembrane protein and its binding to HIV-1 has been shown to involve glycans 
found on the surface of gp120 (69, 70). HIV-1 binding to DC-SIGN enhances the 
efficiency of viral transmission to cells that are susceptible to infection such as CD4+ 
T cells (13, 105, 119, 159). A study by Pohlmann and co-workers showed that the 
DC-SIGN receptor expressed on 293-T cells is able to bind X4 and R5 viruses and 
this binding results in an efficient transfer of the virus to co-cultured T-cells (120). 
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HIV-1 bound to the DC-SIGN receptor can also be internalized by dendritic cells and 
this may help the virus escape surveillance by the immune system (117, 120). When 
dendritic cells come into contact with CD4+ T cells the virus resurfaces in the zone of 
contact between the two cells to form viral synapses that lead to an increased rate of 
infection and replication of the virus (Figure 1.19). However, Burleigh et al. (27) 
reported that the DC-SIGN receptor mediates the infection in cis of immature 
dendritic cells and this plays a critical role in the long term transfer of newly made 
viruses to T cells. Similarly, the DC-SIGN receptor on macrophages is also believed 
to mediate their infection in cis (119).  
 
Figure 1.19: Mechanism of HIV-1 transfer to target cells via C-type lectin 
receptors. The Figure shows HIV-1 capture by means of a C-type lectin receptor 
(CLR) and internalization into a dendritic cell (DC). The arrow indicates the 
migration of the cell to the lymph node to transfer the virus to a CD4+ T cell. This 
Figure was taken from Piquet and Sattenteau (117). 
 
1.4.4. Female genital tract natural defence against HIV-1  
There are several elements in the female genital tract that constitute natural barriers to 
HIV-1 infection. Amongst them is the stratified structure of the epithelial cell lining 
and the acidic pH of the genital environment (38, 99). A study in rhesus macaques 
showed that the thickening of the vaginal epithelium with esterogen protects against 
vaginal challenge with SIV while the thinning of this lining with progesterone 
decreases this protection (90, 137). In addition, the mucus secreted by epithelial cells 
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in the endocervix can provide protection against HIV-1 by constituting a physical 
barrier to infected cells. This mucus also contains anti-viral proteins such as the 
secretory leukocyte protease inhibitors, lactopherin, human-β-defensin (HBD-1) and 
lysozyme (147). Lastly, endocervical cells express the CXCR4 ligand SDF-1 that can 
present a chemical barrier to X4 viruses (99).    
 
1.5.  HIV-1 microbicides 
1.5.1. Introduction 
1.5.1.1.  Overview 
The developing world remains the epicentre of the HIV epidemic with more women 
infected compared to men (http://www.unaids.org). The higher rate of HIV-1 
infection amongst women in the developing world may be explained by their 
economic dependence on men, domestic violence, high incidence of rape, cultural 
norms and their inability to negotiate safe sex practices such as the use of condom 
with their male partners (53). This supports the need for a female-controlled HIV-1 
microbicide i.e. a cervico-vaginally applied product that can prevent the male to 
female transmission of the virus.   
Many agents have been proposed as microbicide candidates to prevent HIV-1 
infection at the site of mucosal transmission. Some of these agents are specific 
inhibitors of HIV-1 infection while others are non-specific. Amongst HIV-1 
microbicides candidates are found compounds that modify the cervico-vaginal 
environment (vaginal milieu protectors) such as buffering agents, those that interact 
with the positively charged viral envelope such as polyanionic polymers, envelope 
inhibitors such as lectins and reverse transcriptase inhibitors. Some of these 
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compounds have already been tested in clinical trials (Table 1.1) while others are still 
in developmental stage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.2. Vaginal milieu protectors 
The low pH of female genital tract has virucidal effect against HIV-1 (147) and this 
pH is due to the production of lactic acid and hydrogen peroxide (H2O2) by 
lactobacillus species, such as lactobacillus acidophilus and lactobacillus crispatus, 
that are part of the resident microbial ecology of a healthy vaginal tract (39, 77, 106). 
However, semen resulting from sexual intercourse render this environment favourable 
to HIV-1 by neutralizing the vaginal acidity (141). BufferGel TM or Carbopol 974 
(BufferGel, ReProtect, Baltimore, MD, USA), a formulated carbopol polymer with a 
buffering agent that has the ability to buffer twice its volume of semen to a pH ≤ 5, is 
a microbicide candidate that acts by maintaining the acidic pH of the vaginal tract. 
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Although, clinical trials in India, Thailand, Malawi and Zimbabwe showed that the 
use of BufferGel TM destroyed the bacterial populations that caused vaginosis (147) 
this formulation does not affect the genital lactobacillus species population. 
BufferGel TM has already passed two phase I safety trials (39, 91, 150) and also 
proved to be safe and accepted amongst HIV-1 infected and uninfected men during a 
penile tolerance study (140).   
Like BufferGel TM,  Acidform TM is also a buffering agent that was originally 
designed for use as a sexual lubricant (39, 106). This formulation has already been 
subjected to two phase I safety trials and one penile tolerance trial (2, 3, 132). In 
addition to the two buffering agents there are also “probiotics” in development aimed 
at achieving the same goal (106).  
 
1.5.3. Surfactants 
 Surfactants render bacteria and viruses non-infectious by solubilising their membrane 
(147). However, a major limitation with surfactants is that they are non-specific i.e. 
they also target host cells. C31G also known as SAVVY® (Cellegy Pharmaceuticals, 
Quakertown, PA, U.S.A) is one of the best known surfactants. This formulation 
consists of cetyl betaine and myristamine oxide and its most important characteristics 
is its ability to dissolve and spread very fast in the genital mucosa (39, 147). In vitro 
studies showed that C31G has a broad-spectrum activity against bacteria and viruses 
including HIV (32, 78). This compound also has sperimicidal activities that may limit 
its use in communities that stand against contraception. However, C31G was tested in 
two phase III clinical trials in Ghana and Nigeria that had to be abandoned because of 
lower than expected rate of HIV seroincidence in the selected populations (39). 
Nonoxynol-9 (N-9) is another well known surfactant that has been studied as a HIV-1 
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microbicide candidate. Although N-9 demonstrated strong anti-HIV-1 activities in 
vitro, this compound was originally manufactured for use as a spermicide or 
contraceptive (53). Two phase III trials were conducted with N-9 in Africa. One 
amongst sex workers in Cameroon and showed no difference in the rate of HIV 
infection between the study group and the placebo group (127). However, this study 
also found that there was an association between the use of N-9 and the higher 
incidence of genital ulcers among trial participants.  The other clinical trial tested the 
use of 52.5 mg of gel-formulated N-9 that had to be applied before and after sexual 
intercourse (147). Upon unblinding the trial it was found that the N-9 gel increased 
the risk of contracting HIV infection by 50% and this risk was even higher in women 
who reported a reduced use of condom. The increased risk of HIV transmission 
associated with N-9 is likely to be related to the high incidence of superficial de-
epithelialisation, changes in the genital microflora as well as the high rate of petechial 
haemorrhage and erythemia associated with this formulation.   
Sodium lauryl sulphate (Invisible Condom, Univesité Laval, Quebec, Canada) 
is a non-specific inhibitor of HIV-1 and other pathogens that cause sexually 
transmitted infections (STI) (39, 118). This compound is liquid at room temperature 
and converts into a gel that coats the vaginal tract and protects against HIV-1 at body 
temperature. Sodium lauryl sulphate has been shown to be safe in two phase I trials 
and in a rabbit model. However, the result of a phase II trial, conducted in Cameroon, 
is still pending.   
1.5.4. Polyanionic polymers  
Polyanionic polymers interact with the positively charged V3 loop of HIV-1 gp120 
(46, 47, 147) and have been shown to be active against both X4 and R5 viruses. In 
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addition to the positive charge of the V3 loop, the charge mediated binding of 
polyanionic polymers is enhanced by the conformational changes that unmask 
charged regions of gp120 during the virus entry into target cells (47).  
Naphthalene sulfonate (PRO2000; Indevus Pharmaceuticals, Lexington, MA, 
USA) and the seaweed derived sulphated polysaccharide carrageenan 
(Carraguard/515, Population Council, New York, NY, USA) are the most studied 
polyanionic polymers (39, 147). PRO2000 has been shown to have anti-HIV and anti-
HSV activities (75); and in a phase I safety trial this compound was shown to be 
generally well tolerated in humans (149). However, although PRO2000 is able to 
inhibit SIV transmission in rhesus macaques it failed a phase III efficacy trial in South 
Africa; this microbicide interaction with semen was mentioned among the possible 
reasons for the failure (124). Carraguard anti-HIV activities was shown in a mouse 
model (115). This formulation was also tested in phase I trials and proved to be safe 
in both HIV-positive and HIV-negative men and women (18, 36, 151). However, a 
phase III clinical trial conducted amongst women in South Africa showed that 
carraguard is not protective against HIV-1 infection (39). However, it should be noted 
that poor adherence from trial participants was also suspected to be a possible cause 
of carraguard lack of efficacy. 
Cellulose sulphate (Ushercell, Polydex Pharmaceuticals, Toronto, ON, Canada 
and Topical Prevention of Conception and Disease [TOPCAD], Chicago, IL, USA) 
binds to HIV-1 gp120 V3 loop and in vitro studies demonstrated this compound 
efficacy against X4 and R5 viruses (133). Cellulose sulphate safety for use in humans 
was shown in a phase I clinical trial (39, 89). However, in a phase III trial a slightly 
higher incidence of HIV-1 infection occurred in the cellulose sulphate group 
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compared to the placebo group (148). This led to this compound being abandoned as a 
HIV-1 microbicide candidate. 
Cellulose acetate phthalate (CAP) is a polyanionic polymer that has a unique 
mode of action against HIV-1. This compound acts synergistically with soluble CD4 
to inhibit the virus infection of cells. Its binding to gp120 results in the formation of 
the hybrid six helix conformation, an intermediate in HIV-1 entry mechanism (96, 
107). However, although similar to the six-helix bundle formed by Env during the 
unhindered viral entry, the one induced by CAP is premature and non-functional. The 
only limitation with the use of CAP as a topical microbicide is against viruses that in 
vitro showed the ability to infect cells independently of the CD4 receptor (147).   
Betacyclodextrin (BCD) is a polyanionic polymer that depletes cholesterol 
from the viral and cellular membrane, therefore, inhibiting the function of their lipid 
rafts (147). Given that the CD4 receptor and HIV-1 co-receptors are located in these 
cholesterol containing rafts, an interference with their functionality inhibits the virus 
entry into cells (87, 122). In addition, the assembly of new viral particles is also 
dependent on the cell membrane lipid rafts, suggesting that BCD may also inhibit the 
budding process of HIV-1 (108, 147).  
Dendrimers are the newest members of the anionic polymers family. These 
compounds are made of a core, interior branches and terminal surface groups for 
selective interaction with specific targets (39). Dendrimers can bind multiple locations 
on different cells at the same time. SPL7013 (Vivagel, Starpharma Holdings Ltd, 
Melbourne, Australia) is the first of this class of compounds to be formulated as a 
microbicide gel. This dendrimer was shown to be protective against the simian/human 
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immunodeficiency virus (SHIV) chimera in a macaque model (72). A 3% formulation 
of SPL7013 is in phase I clinical trials in Kenya and USA.  
 
1.5.5. Reverse transcriptase inhibitors   
Reverse transcriptase inhibitors (RTI) interfere with the conversion of HIV-1 RNA 
into DNA by the viral reverse transcriptase (39). This group of drugs comprises 
nucleotide and nucleoside reverse transcriptase inhibitors (NRTI); these are defective 
analogs of naturally occurring nucleotides and nucleosides, respectively.  However, 
candidate microbicides also include non-nucleoside reverse transcriptase inhibitors 
(NNRTI); they are inhibitors of HIV-1 reverse transcriptase that are not analogs of 
cellular nucleosides or nucleotides (24, 147).  
The thiocarboxanilide derivative UC-781 is a NNRTI microbicide candidate 
that is characterized by a high affinity for HIV-1 reverse transcriptase. It has been 
shown in vitro that cells treated with UC-781 have a long term protection or 
“memory” against HIV-1 (8, 14, 20). UC-781 showed safety for use in humans in a 
phase I clinical trial that evaluated a once-daily dosing of this compound for 6 days 
(39). In addition, this group of microbicides include SJ-3366, produced by Samjin 
pharmaceutical Inc., a homocyclic pyrimidinedione that has a dual mode of action 
against HIV-1. It inhibits both HIV-1 entry and reverse transcription  (147). Lastly, 
TMC120  (4-[{4-[(2,4,6-trimethylphenyl)amino]pyrimidin-2-yl}amino] benzene 
carbonitrile), another NNRTI that showed no toxicity in animal models and showed 
inhibitory activities against HIV in vitro and in vivo, is also found among these 
microbicide candidates (45, 152). There are on going phase I and II clinical trials with 
TMC120.     
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Tenofovir is a NRTI that acts by mimicking adenosine nucleotide (40). Once 
incorporated in the nascent HIV-1 cDNA it prematurely terminates chain elongation. 
Tenofovir has a cellular half-life of 9 to 50 hours depending on the cell type and it can 
be effective in non-dividing cells such as macrophages that have limited 
phosphorylation ability (5, 7, 126). A study by Tsai et al. using macaques model 
showed that pre-exposure and post-exposure prophylaxis with tenofovir protects 
against intravenous challenge with SIV (146). This report was one of the first to 
provide evidence on the possibility of using tenofovir to prevent HIV-1 infection in 
humans. Since then tenofovir has become the leading antiretroviral used in HIV-1 
vaginal microbicide research.  
Recently, a clinical trial conducted amongst South African women in Kwazulu 
Natal using a 1% tenofovir gel within 12 hours before and after sex showed protection 
against heterosexual transmission of HIV-1 (1). More precisely, after 30 months of 
trial the gel was effective in preventing HIV-1 transmission by 39%.  However, the 
study also revealed that women who had a higher adherence to the gel had a higher 
protection compared to those with a lower adherence. HIV-1 RNA genotyping of 
women who got infected during the trial did not reveal the presence of tenofovir 
resistance mutations which suggested that the use of tenofovir as a vaginal gel may 
not result in HIV-1 resistance (1). However, it is not yet known if using the gel over a 
longer period would lead to resistance mutations.  
 
1.5.6. Proteins    
Amongst proteins proposed as HIV-1 microbicide candidates are lectins. These 
compounds inhibit HIV-1 infection of cells by binding to chains of carbohydrates on 
the gp41-gp120 complex (21). The specificity of lectins for viral glycoproteins, their 
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relatively small size and potent anti-HIV-1 activities give them advantage over other 
potential Microbicides. Lastly, CCR5 inhibitors and fusion inhibitors that bind to 
gp41 to inhibit the fusion of the viral envelope with the cell membrane are also among 
HIV-1 microbicide candidate proteins (39).  
 
1.5.6.1. Griffithsin 
Griffithsin (GRFT) is a lectin isolated from the red alga Griffithsia species (103). This 
lectin is a 121 amino acid protein with a molecular weight of ~ 13kDa that have been 
reported by Emau et al. (54) to be able to withstand both acidic and alkaline pH. 
GRFT has a domain swapped dimer structure in which two β-strands of one monomer 
combine with 10 β-strands of the other monomer to form a β prism made of three 
four-stranded sheets (167, 168) (Figure 1.20). Each monomer of GRFT contains three 
binding sites that have high affinity for mannose residues. Both native and 
recombinant GRFT have displayed potent antiviral activities against laboratory strains 
and primary isolates of X4 and R5 viruses (54, 103). A study by O’Keefe et al. 
showed that GRFT produced in the tobacco related plant Nicotiana benthamiana have 
a broad neutralizing activity against different subtypes of HIV-1 (111). This 
recombinant GRFT was also shown to be non-toxic in a rabbit vaginal irritancy model 
and in human cervical explants. GRFT inhibits HIV-1 infection by binding to the 
mannose-rich glycans of the gp41-gp120 glycoprotein complex. Although this 
compound is not HIV-1-specific, it targets mannose-rich arrays that are present on all 
HIV-1 envelope glycoproteins. Since such arrays are uncommon in mammalian cells, 
GRFT is not likely to be toxic to human cells even at relatively high concentrations 
(6, 9).  
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Figure 1.20: A ribbon model of the GRFT dimer.  The two monomers making the 
dimer are shown in blue and green. The N-terminal extension resulting from the 
cloning procedure is shown in red. This Figure was taken from Ziolkowska et al. 
(167).  
                    
1.5.6.2.  Cyanovirin-N  
Cyanovirin-N (CV-N) is a lectin of 101 amino acids and a molecular weight of ~ 11 
kDa. This compound was isolated from the blue green alga Nostoc Ellipsosporum and 
shown to exist in solution as a compact, quasi-symmetric two-domain monomer 
(Figure 1.21a and b). However, CV-N has the crystal structure of a domain swapped 
dimmer (22, 156, 168). 
        a)              b)     
                      
                          
                      
                            
 
Figure 1.21: Ribbon models of CV-N.  (a) The two domains of monomeric CV-N 
are showed in cyan and green.  (b)  Molecular structure of dimerized CV-N. This 
Figure is an adaptation from Ziolkowska and Wlodawer (168).  
 
Each monomer of CV-N has two binding sites for mannose residues (168). Both 
recombinant and native CV-N have shown potent and broad anti-viral activities 
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against a range of viruses including HIV-1 and HIV-2; and like GRFT, CV-N 
neutralizes HIV by binding to mannose-rich glycans of gp41 and gp120 (19, 21, 22, 
55, 110, 123). In addition, Balzarini et al. showed the ability of CV-N to inhibit the 
DC-SIGN mediated HIV-1 subtype B transfer from dendritic cells to CD4+ T cells 
(10). However, HIV-1 was reported to develop resistance to CV-N by mutating 
glycans at positions 230, 332, 339, 386, 392 and 448 (11). This was supported by Hu 
et al. (2007) who also reported that glycan deletion is the pathway used by HIV-1 to 
develop resistance to CV-N (71). Although CV-N has not yet been tested in a human 
clinical trial it is noteworthy that this compound was shown to be effective in 
protecting pigtailed macaques after vaginal and rectal challenges with high dose of 
SHIV 86.9P (144, 145). 
 
1.5.6.3.  Scytovirin    
Scytovirin (SVN) is a lectin isolated from the cyanobacterium scytonema varium  and 
this compound is made of 95 amino acids with a molecular weight of ~ 9.7 kDa (17, 
158). The amino acids sequence of SVN is contained in a single chain with extensive 
internal sequence duplication that divides the molecule into two functional domains. 
The scytovirin domain 1 (SD1) and domain 2 (SD2) are 75% identical and are linked 
together by 5 inter-domain disulfide bonds (95, 168). SVN exists exclusively as a 
monomer that has two binding sites for mannose residues, one in each domain  
(Figure 1.22) (104). Like GRFT and CV-N, SVN inhibits HIV-1 interaction with 
cellular receptors by binding to mannose-rich residues on its envelope. Both the 
native and recombinant SVN were shown to be strongly inhibitory to laboratory 
strains and primary isolates of HIV-1; and Xiong et al. showed that while SD1 has an 
anti-viral activity equaling that of the entire SVN molecule SD2 is significantly less 
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inhibitory to the virus (17, 158). However, unlike GRFT and CV-N, SVN has been 
studied exclusively in vitro. 
 
           
 
 
 
 
 
 
 
Figure 1.22: SVN amino sequence and structure. The Figure shows two different 
views (180º rotation) of a SVN molecule. Yellow and magenta indicate the 
carbohydrate binding residues of SD1 while green and cyan show the carbohydrate 
binding residues of SD2.  This Figure was taken from Moulaei et al. (104). 
 
 
1.5.6.4.   Other HIV-1 microbicide candidate proteins  
PSC-RANTES potently binds the CCR5 co-receptor to inhibit its interaction with 
HIV-1. This protein showed inhibitory activities against all subtypes of HIV-1 in vitro 
(39, 143); and  in vivo a high dose of PSC-RANTES was found to be protective 
against SHIV SF162 in macaques (84). CMPD167 is another CCR5 inhibitor that also 
showed a high protective activity against SHIV in a macaques model (153). 
Additionally, it has been shown that the combination of CMPD167 and BMS-378806 
that binds gp120 and C52L that binds gp41 results in a 100% protection of macaques 
from SHIV challenge. No irritation or toxicity of the genital tract was associated with 
the use of these compounds. Lastly, PRO140, a CCR5 inhibitor, PRO542, a 
tetravalent soluble CD4 construct, T20 and T1249 that bind gp41; thrombospondin 
type I (TSP), a plasma protein that blocks HIV-1 entry; and the pokeweed antiviral 
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protein (PAP) that inhibits HIV-1 replication are also among these candidate 
microbicides (147).  
 
1.6. Microbicides: modes of delivery 
1.6.1. Gels 
Many delivery systems are being studied for dispensing HIV-1 microbicides into the 
female genital tract (106). However, among them gels are the most commonly used as 
so far most clinical trials have been conducted with gel formulated microbicides. 
Although they can sometimes be uncomfortable when applied gels have the advantage 
of being easy to use (106). Often gel formulated microbicides are designed for 
application before sexual intercourse; however, in some cases, such as in the tenofovir 
trial, they have also been applied after sexual intercourse (1).  
 
1.6.2. Vaginal rings 
Vaginal rings as a mode of delivery of HIV-1 microbicides involve the insertion of a 
ring containing an anti-HIV-1 compound into the female genital tract for a long-term 
and continuous release of the anti-viral drug to provide an environment hostile to the 
virus (128). Vaginal rings are made of polymers such as poly(dimethylsiloxane), 
silicon, ethylene vinyl acetate or styrene butadiene (106).  One of the key benefits of 
vaginal rings is that they provide an alternative to users’ sustained adherence. 
TMC120 or Dapiravine is one of HIV-1 potential microbicides being studied for 
delivery through a vaginal ring (106, 128). 
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1.6.3. Tablets and suppositories  
Tablets and suppositories are designed to melt in the genital tract once applied thereby 
releasing the microbicidal agent (106). With these systems the microbicide can be 
delivered over several hours. Tablets are often formulated with mucoadhesive 
polymers and this increases their retention time in the genital tract (4). However, 
some tablets also use silicon matrices. Polystyrene sulfonate and praneem, containing 
purified extracts of azadirachta indica, are amongst HIV-1 microbicide candidates 
studied for delivery as vaginal tablets (128). A major advantage of using tablets and 
suppositories for the delivery of HIV-1 microbicides is that they are already in use as 
delivery systems for various intra-vaginal drugs. For example, cervical ripening prior 
to child birth is achieved by the delivery of a suppository into the genital tract (106).  
 
1.6.4. Nanoparticles 
Nanoparticles are also being researched as potential vehicles for HIV-1 microbicides 
(106). This system involves binding nanoparticles of a noble-metal such as silver with 
an anti-HIV-1 protein for delivery into the genital tract. Nanoparticles offer the 
advantage of being able to protect the anti-viral agent from degradation and also of 
facilitating its penetration into tissues containing HIV-1 target cells  (128). Currently 
PSC-RANTES is being investigated for delivery via nanoparticles (68). A study using 
human ectocervical tissues showed that PSC-RANTES encapsulated into 
nanoparticles has a 4.8 times greater uptake than the nonencapsulated one (128).     
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1.7. Antibodies against HIV-1  
1.7.1. Introduction 
Like with other viruses, an HIV-1 infection induces the synthesis of antibodies in the 
infected individual. Some of these antibodies are able to prevent virus infection of 
cells in vitro and are called neutralizing antibodies; others, however, are not able to 
neutralize the virus and are called non-neutralizing antibodies (12). The main 
difference between neutralizing and non-neutralizing antibodies is that the former 
bind the trimeric form of gp41-gp120 while the latter only recognise the monomeric 
form (101, 121). In addition, some HIV-1 infected individuals develop broadly 
neutralizing antibodies which are able to neutralize heterologous viruses including 
those of other subtypes (61, 94, 102, 138). From these individuals monoclonal 
antibobidies (mAbs) have been isolated and just like the plasma from which they have 
been derived these antibodies have demonstrated potent and broad antiviral activities 
in vitro (12, 16, 23, 29). It is important to note that some of these broadly neutralizing 
antibodies are being studied as potential HIV-1 microbicides (9, 83). 
 
1.7.2. The 2G12 antibody 
The anti-HIV-1 monoclonal antibody 2G12 is broadly neutralizing and targets 
carbohydrates on gp120 (21, 30, 31). The Fab region of 2G12 has a domain swapped 
dimer structure resulting from the exchange of domains between the two arms of the 
antibody heavy chains (Figure 1.23) (30). This monoclonal antibody directly binds 
glycans at positions 332, 339 and 392 (31), while glycans at positions 295, 386 and 
448 indirectly influence the conformation of its epitope (130, 131). Mutations from 
asparagine (N) to alanine (A) at the 295, 332, 339, 386, and 392 glycosylation sites 
have been shown to significantly reduce 2G12 affinity for HIV-1 gp120 (131). 
 40 
Moreover, subtype C viruses are commonly resistant to 2G12 neutralization. This has 
been partly attributed to their frequent lack of the 295 glycosylation site (see Figure 
1.10) as the re-introduction of this glycan only partially restores their sensitivity to 
2G12 (16, 35, 60). 
 
                            
 
 
 
Figure 1.23: A ribbon model of the 2G12 antibody Fab region. The 2G12 Fab 
dimer is shown in complex with mannose8; in cyan are the light chains while the 
heavy chains are shown in purple and red (30). 
 
 
1.7.3. The b12 antibody 
The monoclonal antibody b12 is a HIV-1 broadly neutralizing antibody that binds to a 
conserved region of gp120 overlapping the CD4bs (163). The presence of the 
mannose-rich glycan at position 386 has been shown to play an important role in this 
interaction. Eighty two percent of the b12 epitope is located in the outer domain of 
gp120 (163) that it contacts via its heavy chain complementarity-determining regions 
(CDR) (Figure 1.24). Most importantly, tryptophan 100 of CDR H3 intercalates 
between arginine 419 and N-glycosylated asparagine (asn) 386 of gp120 
(http://www.nature.com  doi: 10.1038/nature05580). The involvement of asn 386 in 
b12 binding to gp120 was also shown by Zwick et al. (169) as mutation to alanine of 
b12 tyrosine 53, a residue that intercalates between threonine 373 and asn 386 of 
gp120, resulted in the reduction of b12 binding to the glycoprotein.  However, three 
other studies reported that the presence of the glycan at position 386 renders HIV-1 
resistant to b12. More precisely Duenas-Decamp et al. showed that asn 386 together 
with arginine 373 decreases HIV-1 sensitivity to b12 (50) and this was supported by 
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Gray et al. and Sanders et al. in studies showing the removal of the 386 glycan 
significantly increased the sensitivity of the virus to this antibody (60, 129). 
a)         b) 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.24: The structure of b12 in complex with gp120. (a) A ribbon model of 
b12 bound to gp120. CDR H 1, 2 and 3 that make contact with the outer domain of 
gp120 are shown in orange, cyan and dark green, respectively. (b) A closer look at the 
interaction between tryptophan 100 of CDR H3 and gp120 asparigine 386 and 
arginine 419. These three amino acids are indicated by arrows. Amino acids in gp120 
and b12 are labelled in italic and normal script, respectively. This Figure was adapted 
from Zhou et al. (163).  
 
1.7.4. Other HIV-1 broadly neutralizing antibodies 
VRC01 is the broadest HIV-1 neutralizing antibody isolated to date as it neutralizes 
over 90% of circulating isolates (162). Like b12 VRC01 binds to the CD4bs; 
however, unlike many CD4bs antibodies its binding to this site avoids conformational 
masking (79) and the glycan that shield the CD4bs. VRC01 broad neutralization 
breadth is partly due to the extensive affinity maturation it undergoes and the fact that 
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87% of its interaction with gp120 is made with the conformationally invariant outer 
domain (162). Although, 13% of VRC01 contact with gp120 involve the bridging 
sheet and the conformationally flexible inner domain this interaction has a minor 
influence on the antibody binding to HIV-1.  
Like VRC01, PG9 and PG16 are potent and very broad HIV-1 neutralizing 
antibodies (154). More precisely, they neutralize 70-80% of circulating HIV-1 isolates 
(113). PG9 and PG16 are somatically related and are derived from the same 
combination of heavy and light chain. In addition, these antibodies target a quaternary 
epitope on gp41-gp120 trimer involving the V2 and V3 loops. Two of the main 
characteristics associated with PG9 and PG16 broad neutralizing activities are the 
extensive affinity maturation they undergo and the unusually long CDR H3 they 
possess (113).  
The monoclonal antibodies 2F5 and 4E10 are HIV-1 broadly neutralizing 
antibodies that target the membrane-proximal external region (MPER) of gp41 (33, 
49, 66, 112). The core of the 2F5 epitope is made of the sequence ELDKWA while 
the sequence NWFDIT forms the core of 4E10 epitope. The binding of 2F5 and 4E10 
to HIV-1 can be divided into two steps that are: attachment to the virion associated 
lipids and binding to the MPER epitope that becomes exposed during the virus-cell 
fusion (94). Together with 2G12, b12, VRC01, PG9, PG16, 2F5 and 4E10 are the 
broadest and most potent HIV-1 antibodies isolated to date. Figure 1.25 summarizes 
the location of these seven antibodies epitopes on trimeric gp41-gp120. 
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Figure 1.25: Summary of 2G12, b12, VRC01, PG9, PG16, 2F5 and 4E10 epitopes 
on gp41-gp120 trimer. The locations of the seven antibodies epitopes are indicated 
by arrows. In addition, the Figure shows the core gp120 in red, glycans constituting 
the 2G12 epitope are shown in white while the rest of gp160 glycans are shown in 
blue, and VRC01 and b12 epitopes are shown in yellow. This Figure was taken from 
McElrath and Haynes (94). 
 
Although not as broad and potent as the antibodies mentioned above, the V3 
loop specific antibody F425-B4e8 has been shown to have cross-neutralizing 
activities against HIV-1 subtype B, C and D isolates (15). F425-B4e8 epitope is made 
of residues surrounding the sequence GPGRA that constitutes the apex of the V3 loop 
in subtype B viruses and Isoleucine 309, arginine 315 and phenylalanine 317 play a 
critical role in this epitope (15). However, much of F425-B4e8/V3 interaction involve 
arginine 315 since this residue mutation to alanine or glutamine markedly reduces the 
antibody affinity for gp120 (114).  
The monoclonal antibody 17b neutralizes HIV-1 by binding to the CD4 
induced (CD4i) epitope that is formed following CD4 binding to gp120 (142). Most 
importantly, 17b prevents HIV-1 entry into cells by inhibiting steps that are 
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subsequent to CD4-gp120 interaction. Furthermore, this antibody binding to gp120 
was shown to be enhanced in the presence of sCD4 and in vitro 17b showed broad 
neutralizing activities against HIV-1 subtypes (142). Lastly, in a study by Decker et 
al. 17b demonstrated potent inhibitory activities against HIV-2 in the presence of 
sCD4 (42). 
 
1.8. Study aims 
The main objective of this study was to investigate the ability of GRFT, CV-N and 
SVN to inhibit HIV-1 subtype C infection of cells and to study the binding sites of 
these lectins on gp120. This was achieved by dividing the study in four parts:  
1. Since HIV-1 subtype B has been shown to be sensitive to GRFT, CV-N and 
SVN the first part of the project involved testing the sensitivity of subtype C 
viruses to these lectins. This section also examined glycans on HIV-1, 
including those in the 2G12 epitope, that are involved in GRFT, CV-N and 
SVN binding to the virus.  
2. While studying the involvement of the 2G12 epitope in GRFT, CV-N and 
SVN binding to HIV-1 we observed that GRFT enhanced the binding of the 
mAb b12 to HIV-1. We, therefore, investigated the ability of GRFT to expose 
the CD4bs, thereby, making it more accessible to CD4bs specific antibodies. 
In this section we also studied whether GRFT synergized with these antibodies 
to neutralize HIV-1.   
3. The DC-SIGN receptor plays an important role during the sexual transmission 
of HIV-1; it mediates the transfer of the virus to its target cells. Therefore, in 
this part of the project we investigated GRFT, CV-N, and SVN inhibition of 
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HIV-1 binding to the DC-SIGN receptor as well as their inhibition of the DC-
SIGN receptor-mediated transfer of the virus to target cells.   
4. Because HIV-1 subtype B has been shown to develop resistance to CV-N we 
investigated the ability of the subtype C virus to develop resistance to GRFT, 
CV-N and SVN. We also analyzed glycans on the viral envelope that are 
involved in this resistance.  
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ABSTRACT 
Glycans on the HIV-1 trimer protect neutralization sensitive epitopes and contribute to 
the structural integrity of the envelope. Those on gp120, particularly the mannose-rich 
glycans are targets for lectins that can inhibit virus entry into cells. We examined the 
ability of HIV-1 subtype C to develop resistance to the inhibitory lectins, griffithsin 
(GRFT), cyanovirin-N (CV-N) and scytovirin (SVN) which bind multiple mannose-rich 
glycans on gp120. HIV-1 strains Du179, Du151, Du422 and COT9 cultured under 
escalating concentrations of the three lectins became increasingly resistant to these 
compounds tolerating 2 to 12 times their 50% inhibitory concentrations. Envelope 
sequence analysis of lectin-selected viruses showed that most had deletions of 1 to 5 
mannose-rich glycans on gp120. Glycosylation sites at positions 230, 234, 241, 289 
located in the C2 region and 339, 392 and 448 in the C3-C4 region were affected. 
Differences in the glycan deletion patterns in response to the three lectins were noted, 
although sites 230, 392 and 448 were common. Furthermore, deletions and insertions of 
up 4 amino acids near mannose-rich glycosylation sites in the variable region 4 (V4) of 
gp120 were also observed. These data suggest that gp120 deglycosylation and 
rearrangement of glycans are mechanisms of HIV-1 subtype C escape from GRFT, CV-N 
and SVN. They also suggest that the C2, C3 and V4 regions are important for lectin 
binding to the viral envelope.   
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INTRODUCTION 
The surface of the HIV-1 envelope is populated with glycans that play an important role 
in protecting neutralization sensitive epitopes (21, 26, 27, 31, 43, 44, 49), promoting 
gp120 structural integrity and mediating interaction with cellular receptors (20, 28-30, 
32). The majority of glycans on the HIV-1 envelope trimer are mannose-rich comprising 
7 to 9 terminal mannose residues (9, 18) although the precise number and location 
remains elusive. Complex glycans with terminal sialic acid residues are likely also 
present (27). Mannose-rich glycans are targets for lectins or carbohydrate binding agents 
(CBAs) such as griffithsin (GRFT), cyanovirin-N (CV-N) and scytovirin (SVN) isolated 
from naturally occurring algae (8, 10, 36-38, 50, 51). These lectins showed potent and 
broad anti-HIV-1 activities in vitro and are, therefore, being investigated for use in HIV-1 
prevention, mostly in the form of microbicides (3, 39, 41, 42).  
Since the neutralization activity of lectins involves interaction with glycans, one 
potential mechanism of HIV-1 escape from these compounds is deglycosylation. Indeed 
studies on HIV-1 subtype B have shown deletion of mannose-rich glycans is a 
mechanism of resistance to CV-N (6, 23). More specifically, Balzarini and colleagues 
showed that loss of mannose-rich glycans at positions 230, 289, 295, 332, 339, 386, 392 
and 448 was associated with resistance in HIV-1IIIB and HIV-1NL-4.3 (6). Similarly, Hu et 
al. reported the deletion of six of these glycans including those at positions 230 and 386 
also on HIV-1IIIB cultured under escalating concentrations of CV-N (23). In addition, 
HIV-1 resistance to the lectins Galanthus nivalis agglutinin and Hippeastrum hybrid 
agglutinin, was reported to occur via partial envelope deglycosylation (4, 5). 
Furthermore, HIV-1 resistance to the broadly neutralizing antibody 2G12, that targets 
glycans on gp120, involves the deletion of mannose-rich glycans and this is supported by 
the fact that most subtype C viruses are resistant to this antibody due to their lack of the 
295 glycosylation site (7, 13, 22, 33). Thus, partial deglycosylation is an escape 
mechanism frequently used by HIV-1.    
The glycosylation pattern on the HIV-1 subtype C envelope differs from subtype 
B (47), and the ability of these viruses to develop resistance to lectins is unknown. In the 
current study we describe the mechanism of resistance to CV-N among four subtype C 
primary viruses and show that it was similar to subtype B, involving the deletion of 
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mannose-rich glycans on the envelope. Some of these glycans were the same as those 
already identified for subtype B. However, we also observed the involvement of the 234 
glycan, not previously shown, and amino acids deletion in the V4 region. In addition, 
HIV-1 escape from GRFT and SVN followed a similar pathway to CV-N. Thus, changes 
of glycosylated and non-glycosylated amino acid sequences accompanying resistance to 
these three lectins suggest multiple mechanisms of escape.  
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MATERIALS AND METHODS  
Viruses, cell lines and lectins: Infectious HIV-1 subtype C, R5-using virus Du151 and 
Du422 were isolated from acute infections while the R5X4 Du179 was isolated from a 
chronic infection in South Africa (45). COT9 is a R5 isolate from a chronically infected 
pediatric patient (14). The pSG3Δenv plasmid was provided by Dr. Beatrice Hahn. The 
TZM-bl cell line was from the NIH Reference and Reagent Program (Cat No 8129) while 
the 293T cell line was obtained from the American Type Culture Collection. These two 
cell lines were cultured in DMEM containing 10% fetal bovine serum (FBS). Cell 
monolayers were disrupted at confluence by treatment with 0.25% trypsin in 1 mM 
EDTA. Recombinant GRFT, CV-N and SVN were purified from E. coli at the National 
Cancer Institute, MA, USA (8, 10, 36).  
 
Selection of GRFT, CV-N and SVN resistant viruses: One thousand TCID50 of each HIV-
1 subtype C infectious isolate were grown under escalating concentrations of GRFT, CV-
N and SVN. Viruses were cultured in 2 mL of 4 x 106 peripheral blood mononuclear cells 
(PBMC), depleted of CD8+ T cells by means of RosetteSep CD8 depletion cocktail 
(StemCell Technologies, Vancouver, Canada). The starting concentrations of the lectins 
were the IC50 (50% inhibitory concentration) for each virus. Cultures without lectins were 
included as experimental controls. All cultures were maintained in RPMI 1640 containing 
20% FBS and IL2 (0.05 µg/mL). Viruses were passaged every 7 days by transferring 500 
µL of the previous culture into fresh CD8 depleted PBMC. The concentration of GRFT, 
CV-N and SVN was increased whenever the p24 antigen level in the lectin containing 
cultures was similar or higher than the control cultures. When these levels were lower the 
lectin concentration was reduced. After every passage 500 µL aliquots of culture 
supernatants were stored at -70 ºC for genotyping and neutralization assays.  
 
HIV-1 neutralization assay in peripheral blood mononuclear cells: The neutralization 
assay in PBMC was carried out as described by Bures et al. (11). Briefly, a three-fold 
dilution series of GRFT, CV-N, and SVN in 40 µL of RPMI 1640 containing 20% FBS 
and IL2 (growth medium) was prepared in triplicate in a U-bottom 96-well plate. Five 
hundred TCID50 of the HIV-1 isolate in 15 µL of growth medium was added to each well 
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and the plate was incubated at 37ºC for 1 hour. This was followed by the addition of 5 x 
105 cells/well/100 µL of phytohemagglutin/IL-2 stimulated PBMC (PHA-PBMCs). After 
an overnight incubation, cells were washed 3 times with RPMI 1640 containing 20% FBS 
and resuspended in 155 µL of fresh growth medium. The culture supernatant was 
collected twice daily and replaced with an equal amount of fresh growth medium. The 
p24 antigen concentration in the virus control wells was measured by ELISA using the 
Vironostika HIV-1 Antigen Microelisa System (Biomerieux, Boseind, the Netherlands). 
Levels of p24 in the lectin cultures were measured at the time-point corresponding to the 
early part of the linear growth period of the virus control (48). The 80% inhibitory 
concentrations (IC80) were calculated by plotting the lectin concentration versus the 
percentage inhibition in a linear regression using GraphPad Prism 4.0.  
 
HIV-1 envelope amplification and sequencing: HIV-1 RNA was extracted from stored 
aliquots of infectious viruses grown under increasing concentrations of GRFT, CV-N and 
SVN. RNA was reverse transcribed to cDNA using the Superscript III Reverse 
Transcriptase according to the manufacturer’s instructions (Invitrogen, CA). For both the 
single genome amplification (SGA) and the total population amplification, envelope gene 
PCR was carried out as described by Salazar-Gonzalez et al. (40). The PCR products 
were gel purified using the Qiagen Gel Purification Kit according to the manufacturer’s 
instruction (Hilden, Germany), sequenced using the ABI PRISM Big Dye Terminator 
Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA) and 
resolved on an automated genetic analyzer. Changes in the sequenced envelopes were 
identified using Sequencher v.4.5 (Genecodes, Ann Arbor, MI), Clustal X (ver. 1.83) and 
Bioedit (ver. 5.0.9).  
   
Generation of mutants Env-pseudotyped virus stock: Glycosylation sites and amino acid 
deletions and insertions associated with GRFT, CV-N and SVN resistance were 
introduced in HIV-1 envelope clones using the QuikChange Site Directed Mutagenesis 
Kit (Stratagene, LaJolla, CA). The presence of the mutations was confirmed by 
sequencing as described above. HIV-1 pseudoviruses were generated by co-transfection 
of the Env and pSG3Δenv plasmids (44) into 293T cells using the Fugene transfection 
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reagent (Roche Applied Science, Indianapolis, IN). This was followed by the 
quantification of the TCID50 of each virus stock by infecting TZM-bl cells with serial 5-
fold dilutions of the supernatant in quadruplicate in the presence of DEAE dextran (37.5 
µg/mL) (Sigma-Aldrich, St. Louis, MO). After 48 hours of culture, HIV-1 infection was 
measured using the Bright Glo™ Reagent (Promega, Madison, WI), according to the 
manufacturer’s instructions. Luminescence was quantified in a Wallac 1420 Victor 
Multilabel Counter (Perkin-Elmer, Norwalk, CT) and the TCID50 was calculated as 
described elsewhere (25). 
 
Single cycle neutralization assay (TZM-bl assay): The pseudovirus neutralization assay 
was carried out as described previously (35). Briefly, three-fold dilution series of GRFT, 
CV-N and SVN in 100 µL of DMEM with 10% FBS (growth medium) were prepared in 
a 96-well plate in duplicate. This was followed by the addition of 200 TCID50 of 
pseudovirus in 50 µL of growth medium and the mixture was incubated for 1 hour at 
37ºC. Then 100 µL of TZM-bl cells at a concentration of 1 x 105 cells/mL in 10% FBS 
DMEM containing 37.5 µg/mL of DEAE dextran was added to each well and the plate 
was placed at 37ºC for 48 hours. HIV-1 infection was evaluated by measuring the activity 
of firefly luciferase. Titers were calculated as the inhibitory concentration that causes 
50% reduction (IC50) of relative light unit (RLU) compared to the virus control (wells 
with no inhibitor) after the subtraction of the background (wells without both the virus 
and the inhibitor).  
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RESULTS      
Replication of HIV-1 subtype C isolates in the presence of sub-inhibitory 
concentrations GRFT, CV-N and SVN  
HIV-1 subtype B has previously been shown to develop resistance to CV-N after repeated 
passages in the presence of escalating concentrations of this compound (4, 5, 23). Since 
the glycosylation patterns of HIV-1 subtype C envelope differs (47), we determined the 
ability of viruses of this subtype to develop resistance to CV-N and two other lectins, 
GRFT and SVN. Four primary isolates were cultured in CD8 depleted PBMC in the 
presence of increasing lectin concentrations for 11 to 22 weeks, starting with the 
concentration equal to the IC50 for each compound (Table 1). Viral growth was measured 
weekly by p24 antigen ELISA which showed variation during the course of the 
experiment and on some occasions was markedly reduced in the lectin-containing 
cultures when compared to the control (culture containing no lectin) (Figure 1). When 
this happened the lectin concentrations were reduced accordingly in order to facilitate 
ongoing replication.  
 The Du179 isolate developed the greatest loss of sensitivity to all three 
compounds, tolerating at least 10 times the starting concentration of each lectin (Table 1). 
Du151, Du422 and COT9 grew at 3 times the starting concentrations of GRFT and SVN 
and 5 times the starting concentration of CV-N (Table 1). Altogether, these data showed 
that the continuous growth of HIV-1 subtype C under lectin selective pressure resulted in 
increased resistance to these compounds.  
 
Lectin-selected isolates showed decreased sensitivity and cross-resistance  
We next determined whether viruses cultured in the presence of GRFT, CV-N and SVN 
showed reduced sensitivity to these compounds in the PBMC neutralization assay, using 
an 80% neutralization (IC80) cut-off (12, 19). Du179 selected by the 3 lectins 
(Du179/GRFT.R, Du179/CV-N.R and Du179/SVN.R) showed a >5 fold increase in IC80 
compared to the control viruses, passaged in the absence of the lectin (Figure 2A). For 
Du151 and Du422 there was an increase in IC80 that ranged from 2 to 4 fold for all 3 
lectins (Figure 2B and C), while for COT9, the GRFT resistant virus showed a ~2 fold 
increase in IC80 (Figure 2D). However, there was no change in IC80 for COT9 cultured 
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under CV-N and SVN, despite their ability to grow under increased concentrations of 
these lectins.   
We next investigated whether viruses that were resistant to each compound also 
showed cross-resistance to the other two lectins. We used Du179 for this study as this 
virus developed the greatest resistance to the lectins. Du179/GRFT.R showed a ~3 fold 
increase in resistance to CV-N and SVN neutralization (Figure 3). A similar increase was 
observed for Du179/CV-N.R against GRFT and SVN. Lastly, Du179/SVN.R developed 
strong resistance to GRFT with its IC80 increasing ~7 fold. However, this virus resistance 
to CV-N increased only ~3 fold. These data suggest that resistance to one lectin confers 
cross-resistance to the other two probably as a result of the overlapping glycans binding 
sites on gp120 (1).    
 
Resistance was associated with amino acid changes and deletions at and around 
mannose-rich glycosylation sites  
In HIV-1 subtype B, resistance to CV-N occurred through the deletion of mannose-rich 
glycosylation sites (4, 5, 23). In order to assess whether this was also the case in subtype 
C, we compared the full envelope sequences of the total viral population of both wild 
type (viruses passaged in the absence of the lectin) and their corresponding resistant 
samples. Unpassaged Du179, Du151 and COT9 each had 10 intact mannose-rich 
glycosylation sites while Du422 had nine. All four viruses lacked the 295 glycosylation 
site as is common among subtype C viruses (26, 47). Of the 12 selected viruses (four for 
each lectin), nine had deletions of glycans on gp120 with no changes in gp41 
glycosylation patterns. Out of the 11 glycosylation sites on gp120 that have been 
confirmed to contain mannose-rich glycans (27), seven were involved in resistance to 
GRFT, CV-N and SVN (Figure 4). Deletions of the 230, 392 and 448 glycans were 
observed among viruses selected by all three lectins with the 448 glycan observed in 6 
out of the 12 selected viruses. Except for position 289, deletions at the seven sites 
occurred in response to more than one lectin, in agreement with the overlap of their 
binding sites.  
Examination of glycans changes to individual lectins showed that the greatest 
number of deleted glycans was conferred by GRFT selection (Table 2). The loss of the 
 106 
glycan at position 339 occurred in three out of four GRFT resistant viruses (Table 2 and 
Figure 4), with those at position 230 and 234 occurring in two. In GRFT resistant Du179 
there was also the deletion of the 442 glycan, predicted to be complex in studies 
conducted with monomeric gp120 (26, 27). The loss of sensitivity to GRFT in Du422 
restored the glycan at position 386 that was absent in the wild type virus (Table 2). With 
CV-N resistant viruses, the loss of the 448 glycan was the most common, occurring in 
half of these viruses (Table 2). However, we did not observe a change in COT9 and 
Du422 sequences that accompanied their reduced sensitivity to CV-N. Three out four 
SVN resistant viruses had the 448 deglycosylation while two out four had the 339 
deletion (Table 2). The same as with GRFT, SVN resistance restored the 386 glycan in 
Du422. Lastly, similar to CV-N, COT9 resistance to SVN was not associated with an 
apparent change in glycan.  
In addition to gp120 deglycosylation, we observed deletions and insertions of 
amino acid sequences near mannose-rich glycosylation sites located in the fourth variable 
(V4) region. GRFT resistance was associated with the deletion of four amino acids at 
position 400-403 and 396-399 in Du179 and COT9, respectively (Figure 5A and D). 
However, in Du422 resistance to GRFT resulted in the insertion of five amino acids at 
position 398-402 (Figure 5C). Similarly, CV-N resistance led to the deletion of four 
amino acids in Du179 at position 392-395 (Figure 5A). In Du422, SVN resistance 
resulted in the insertion of five amino acids at position 398-402, this was similar to GRFT 
(Figure 5C). We observed no deletions or insertions of amino acids in Du151 under the 
selective pressure of any of the three lectins. In conclusion our data show that HIV-1 
subtype C developed resistance to GRFT, CV-N and SVN by deleting amino acids that 
may result in shifting the position of neighboring glycans, this in addition to directly 
deleting these glycans.  
 
Single genome amplification of GRFT, CV-N and SVN resistant viruses 
Since the loss of multiple glycans observed by total viral population sequencing could be 
the result of a mixture of viruses carrying fewer deglycosylations, we performed single 
genome amplifications (SGA) of gp160. We selected Du179 for this experiment since it 
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was the most deglycosylated of all viruses studied. Using SGA we isolated seven clones 
from GRFT and CV-N selected viruses and six clones from the SVN selected virus.  
All but one GRFT clone had five deglycosylation involving the 230, 234, 339, 
442 and 448 sites. The remaining clone had the deletion of the 393 glycosylation site in 
addition to these sites making its deglycosylation pattern similar to the total population 
sequence. Furthermore, every GRFT clone had the deletion of four amino acids in V4 
mainly at position 400 to 403. For CV-N, most clones had more glycans deletions than 
the total population sequence with the majority having four to five deglycosylation 
compared to only three in this sequence. Also the 234 and 442 deletions observed in most 
CV-N clones were absent in the total population sequence. However, similar to this 
sequence, all clones had the deletion of four amino acids in V4. With SVN, in most cases, 
both the number and deglycosylation pattern of isolated clones were similar to the total 
population sequence although unlike it, one had the 442 deletion while two carried 
deletions of amino acids in V4. Lastly, almost all GRFT, CV-N and SVN clones had the 
sequence GPGK at the tip of the V3 loop changed to GPGQ that is common in viruses 
using the CCR5 co-receptor (17). Taken together, these data show that populations of 
GRFT, CV-N and SVN resistant viruses comprise differentially deglycosylated clones.   
 
Confirmation of resistance conferring mutations by site-directed mutagenesis  
To confirm the association between glycans and V4 amino acid deletions observed in 
GRFT, CV-N and SVN resistant viruses (shown in Table 2 and Figure 5) and increased 
resistance to the lectins, we introduced these deletions into corresponding wild type 
cloned envelopes by site-directed mutagenesis. Sensitivity to the three lectins between 
mutant viruses and their wild type counterparts was compared in a TZM-bl cell 
neutralization assay. The introduction of glycans and V4 amino acid deletions associated 
with GRFT and SVN resistance in the four cloned envelopes caused a decrease in HIV-1 
sensitivity to the lectins judging from the increased IC50 of the mutant viruses (Table 3). 
There was a ~3 fold decrease in GRFT sensitivity while the decrease in sensitivity to 
SVN ranged from 5 to 16 fold. When we introduced glycans and amino acids deletions 
associated with CV-N resistance in Du179.14 and Du151.2 we obtained pseudoviruses 
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that were unable to infect TZM-cells. Nevertheless, these data suggest that the changes 
we observed in HIV-1 gp120 sequence were indeed resistance-conferring mutations.  
Sensitivity to HIV-positive plasma of GRFT and SVN resistant viruses  
HIV-1 resistance to CV-N has been shown to be associated with increased sensitivity to 
HIV-positive sera due to loss of glycans (23). Therefore, we investigated whether GRFT 
and SVN resistant viruses, generated by site directed mutagenesis, had increased 
sensitivity to six HIV-positive plasma samples from chronically infected subjects using 
the neutralization assay in TZM-bl cells. Du179-GRFT.RM and COT9-GRFT.RM were as 
sensitive as the wild type viruses to most of the samples tested (Table 4). However, 
Du151-GRFT.RM mostly showed a decrease in sensitivity, a trend that was partly 
followed by Du422-GRFT.RM (Table 4). There was no change in sensitivity to five of the 
six plasma samples for Du179-SVN.RM and Du422-SVN.RM while Du151-SVN.RM and 
COT9-SVN.RM showed an increase in sensitivity in most cases. In all, our data suggest 
that HIV-1 escape from GRFT and SVN can in some cases affect sensitivity to plasma 
antibodies from HIV-1 positive individuals.       
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 DISCUSSION 
In this study we demonstrated that the continuous growth of HIV-1 subtype C isolates 
under escalating concentrations of GRFT, CV-N and SVN resulted in reduced sensitivity 
to these lectins. This was associated with the deletion of 1 to 5 mannose-rich glycans on 
gp120 and in some cases insertions or deletions of amino acids sequences near mannose-
rich glycosylation sites. We confirmed these associations by site-directed mutagenesis of 
envelope clones. This study is the first to report the mechanism of HIV-1 subtype C 
resistance to GRFT, CV-N and SVN, contributing to a better understanding of the gp120 
binding sites of these compounds.  
The association between mannose-rich glycans deletions on subtype C viruses and 
increased resistance to GRFT, CV-N and SVN is consistent with reports showing that 
these deletions mediate HIV-1 subtype B resistance to CV-N (6, 23, 46). However, it 
should be noted that these studies used laboratory adapted strains while our study was 
based on circulating primary isolates. The deleted glycans were located in the C2, C3, V4 
and C4 regions of gp120 and suggest these regions are involved in the lectins binding to 
the viral envelope. As shown in Figure 7 the structural arrangement of gp120 exposes the 
C2, C3, V4 and C4 and, therefore, renders them available to interact with the lectins. V4 
in particular may be of prime importance to GRFT, CV-N and SVN binding to gp120 
given that in addition to the removal of glycans there were significant deletions and 
insertions of amino acids in this region in many resistant viruses. These changes in V4 
amino acid sequence were near mannose-rich glycosylation sites, thus, probably affecting 
glycans exposure. This finding is in agreement with Witvrouw and colleagues who 
showed that HIV-1 cultured in increasing concentration of CV-N had amino acids 
deletions in V4 (46). Similar to V4, the C2 region is likely to play an important role in the 
interaction of the lectins with HIV-1 since, compared to other regions, it contains the 
highest density of mannose-rich glycans and also had the highest level of deglycosylation 
in our study (Figures 5 and 7). The symmetric arrangement of mannose binding sites on 
GRFT and CV-N (50, 51) and the observation that some deleted glycans were in close 
proximity of each other (Figure 7) suggests that these lectins may cross-link glycans on 
the viral envelope and this is consistent with what has been previously shown for GRFT 
(38). In addition, the spatial arrangement of the 339 and 392 glycans, both deleted under 
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GRFT and SVN selective pressure, suggests that this cross-linking may involve glycans 
on different regions of gp120.  
The observation that in all cases resistance to the lectins was accompanied by the 
deletion of mannose-rich glycans exclusively located in gp120 suggests that glycans in 
gp41 are not involved in GRFT, CV-N and SVN interaction with HIV-1, in agreement 
with Hu and colleagues (23). In some Du179 resistant viruses we observed the deletion of 
the 442 glycosylation site which does not contain a mannose-rich glycan, as shown on 
monomeric gp120 (27). However, recent studies indicated that, contrary to monomeric 
gp120, glycans on gp120 trimer are more resistant to mannose-trimming that generates 
complex glycans (9, 18). Thus, it can be speculated that on the later the 442 site contains 
a mannose-rich glycan. The observation of the 448 deletion in 50% of selected viruses 
suggests this glycan plays an important role in GRFT, CV-N and SVN binding to gp120. 
This agrees with Huang and colleagues who showed that the 448 glycan was critical for 
GRFT interaction with gp120 (24). The  involvement of the 230, 392 and 448 glycans in 
resistance to the three lectins is in agreement with a previous study that showed resistance 
to CV-N involved the loss of these three glycans on HIV-1 subtype B viruses (6). 
Furthermore, the lack of deglycosylation at position 262 is consistent with previous 
subtype B studies (6, 23). However, it is likely that in some cases there are subtype-
specific pathways to resistance. For example, the 289 glycan was lost in subtype B 
viruses that developed resistance to CV-N (23) while none of the CV-N resistant viruses 
studied here showed this loss. Previously we showed the concomitant absence of the 234 
and 295 glycosylation sites renders HIV-1 naturally resistant to GRFT, CV-N and SVN 
(1). In the current study we observed the deletion of the 234 glycosylation site in resistant 
viruses of the three lectins suggesting this glycan can participate in both natural and in 
vitro induced resistance to these compounds.  
Our data did not show an association between the number of deleted mannose-
rich glycans and the concentration of GRFT, CV-N and SVN the viruses tolerated. For 
example the highest concentrations of GRFT that Du151 and Du422 withstood were 
similar although these viruses lost four and one mannose-rich glycan, respectively. The 
same observation was made when comparing the SVN resistant Du151 and Du422. This 
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supports our study that suggested that GRFT, CV-N and SVN sensitivity is more affected 
by the position of deleted mannose-rich glycans than by their number (1).  
In this study we showed that a population of GRFT, CV-N and SVN resistant 
viruses can consist of individual strains that have varying patterns of glycan loss. This 
was not apparent when we analyzed the envelope sequences of the bulk population of 
Du179, Du151, Du422 and COT9 resistant viruses. However, we were able to observe 
this by SGA of GRFT, CV-N and SVN resistant Du179. To a certain extent this mixed 
population of differentially deglycosylated strains should have been expected since, as 
already stated, we previously showed that the number of deleted mannose-rich glycans is 
less important than their position (1). Due to this, viruses that have different levels of 
deglycosylation will tend to coexist in a given resistant population as long as they have 
glycan losses that render them resistant to the lectins. It can as well be speculated that the 
presence of strains with different levels of glycan loss is the result of differences in their 
mechanisms of escape.   
Compared to the other viruses we used, Du179 developed the highest resistance to 
the lectins. This difference is probably not caused by the number or pattern of mannose-
rich glycosylation sites on these viruses since like COT9 and Du151, Du179 lacked only 
the 295 glycosylation site. It is also unlikely that the initial sensitivity of these viruses to 
GRFT, CV-N and SVN played a role in the extent to which they developed resistance to 
the lectins because in most cases they had similar sensitivity to these compounds. 
However, Du179 was the only dual-tropic virus tested here (16, 45). Thus, testing a larger 
number of dual tropic viruses and comparing them to non-dual tropic viruses may reveal 
to which extent the R5X4 property affects the rate at which HIV-1 develops resistance to 
GRFT, CV-N and SVN. Here it is interesting to note that we previously showed GRFT 
inhibits HIV-1 infection of cells by interfering with the co-receptor binding to the virus 
(2). Therefore, it may be possible, at least in the case of GRFT, that the dual tropic 
property might have played a role in Du179 higher escape rate. Note as well that all but 
one Du179 clone (Figure 6) had the GPGQ sequence at the tip of the V3 loop that is 
characteristic of R5 viruses (15, 17), suggesting that Du179 may have given prominence 
to the use of the CCR5 co-receptor under the lectins selective pressure.  
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The level of resistance to the lectins observed in our study was not as high as 
previously shown (6, 46). For example, Balzarini and colleagues, growing HIV-1 under 
escalating concentration of CV-N in CEM cells obtained viruses that could tolerate up to 
20 times the starting concentration of this lectin (6) while our viruses tolerated only 2 to 
12 times the starting concentrations of GRFT, CV-N or SVN. The reason for this partial 
resistance may be due to our use of primary cells that probably did not support HIV-1 
replication the same as it might be the case in the cell line used by these investigators. 
Also our viruses were circulating isolates which may have different replication capacity 
compared to molecular clones used in previous studies (6, 23, 46).  
GRFT, CV-N and SVN are among leading CBAs that are being studied for use in 
HIV-1 prevention. However, until now much of what we know about HIV-1 resistance to 
these lectins is the result of studies conducted with subtype B viruses that compared to 
subtype C have a different glycosylation pattern (47). Thus the current study makes an 
important contribution to our understanding of the mechanism of resistance to GRFT, 
CV-N and SVN in HIV-1 subtype C viruses, the main cause of HIV infections around the 
world. In addition, the extensive loss of glycans and amino acid sequence changes 
associated with resistance to the three lectins may indicate the high genetic barrier the 
virus needs to overcome in order to become resistant to these compounds. This is 
supported by the observation that our viruses’ resistance to the lectins was relatively low. 
However, since partial resistance to these lectins is more likely to happen than complete 
resistance, it is important to understand its mechanism. Taken together, our study 
supports further research in the use of these compounds to prevent the spread of HIV-1.       
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LEGENDS 
 
Figure 1. In vitro generation of GRFT, CV-N and SVN resistant viruses. HIV-1 
subtype C Du179 (A), Du151 (B), Du422 (C) and COT9 (D) were cultured under 
escalating concentration of GRFT, CV-N and SVN. The concentration of each lectin was 
gradually increased or reduced depending on whether the viral growth in the culture was 
the same, higher or lower than the control culture (containing no lectin) as determined by 
p24 ELISA. The axis on the left and right of each graph indicate the p24 and lectin 
concentration, respectively. The arrows show the lectin concentration at the time the virus 
was isolated.   
 
Figure 2. GRFT, CV-N and SVN escape viruses showed a decreased sensitivity to 
the lectins in a PBMC neutralization assay. HIV-1 subtype C Du179 (A), Du151 (B), 
Du422 (C) and COT9 (D) resistant to GRFT, CV-N and SVN were tested against the 
three lectins in a PBMC neutralization assay. The neutralization of HIV-1 infection was 
measured by p24 ELISA and the IC80 of the resistant virus and the corresponding wild 
type were determined by linear regression.   
 
Figure 3. GRFT, CV-N and SVN selected viruses from Du179 show cross resistance 
in a PBMC neutralization assay. GRFT (A), CV-N (B), and SVN (C) resistant Du179 
were tested against GRFT, CV-N and SVN. HIV-1 neutralization was measured by p24 
ELISA and the IC80 of the resistant virus (grey) and the corresponding wild type (white 
bar) were determined by linear regression.   
 
Figure 4. Mannose-rich glycosylation sites deleted in GRFT, CV-N and SVN 
resistant viruses. The X-axis shows the positions of mannose-rich glycans deleted in the 
four isolates under lectin selective pressure. The positions of glycans are numbered 
according to the HxB2 virus (27) and were identified by sequence analysis. The Y-axis 
shows the number of resistant viruses of the four isolates that had the deletion.  
 
Figure 5. Mannose-rich glycans deglycosylation and amino acid deletions and 
insertions in HIV-1 resistant viruses. The regions and positions of the changes 
observed in Du179 (A), Du151 (B), Du422 (C) and COT9 (D) are shown. The sequence 
of the deleted and inserted amino acids (aa) are also shown. The arrows indicate the 
location of the deletion or insertion in each virus. Symbols show glycans that were 
deleted in GRFT (*), CV-N (○) and SVN (∆) resistant viruses. The red color indicates 
that the glycan was deleted in resistant viruses of all three lectins while orange means it 
was added due to lectin selection.  
 
Figure 6. Amino acid sequence of isolated GRFT, CV-N and SVN resistant Du179 
clones. GRFT, CV-N and SVN resistant Du179 clones gp120 sequence isolated by single 
genome amplification. The grey shading shows the presence of a potential mannose-rich 
glycosylation site, yellow shading indicates the site deletion while the red box shows the 
tip of the V3 loop (34). Note that the glycan at position 393 is labelled as 392 in the text 
for comparison with other viruses. 
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Figure 7. Positions of mannose-rich glycosylation sites associated with resistance. 
Mannose-rich glycans on gp120 (Protein Data Bank ID 1GC1) deleted in GRFT, CV-N 
and SVN resistant viruses. Regions of gp120 associated with deleted glycans (shown as 
spheres) are color coded. The picture was created and visualized using PyMOL (DeLano 
Scientific LLC, South San Francisco, CA, USA, http://www.pymol.org). 
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A.                                                          Du179 
 
 
 
 
 
 
 
 
 
 
 
B.       Du151 
 
 
 
 
 
 
 
C.      Du422 
 
 
 
 
 
 
 
 
 
 
D.                                                         COT9                                               
 
 
 
 
 
 
 
     
  
(*) Glycans changed in GRFT resistant virus, (○) removed in CV-N resistant virus and 
(∆) changed in SVN resistant virus. In red are glycans that were deleted in resistant 
viruses of all three lectins. In orange is the glycan that was added under lectin selective 
pressure.  
GRFT.R: 4 aa deletion (400-
403, aa sequence TNSN) 
GRFT.R and SVN.R: 5 aa insertion 
(398-402, aa sequence NESKS)  
* * 
* 
∆ 
* 
* * * * ○ ∆ ∆ 
∆ ∆ * * ∆ 
GRFT.R: 4 aa deletion (396-
399, aa sequence TPNY) 
CV-N.R: 4 aa deletion (392-395, aa 
sequence INSS) 
Figure 5 
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Given the difficulties of finding an effective HIV-1 vaccine, microbicides offer a suitable 
alternative for infection prevention. The case for the use of microbicides against HIV-1 
has been strengthened by the result of the CAPRISA 004 trial that showed for the first 
time that vaginally applied gels containing tenofovir can prevent up to 39% of infections 
(1). However, the potential complications that may arise by utilizing antiretrovirals as 
microbicides, such as the emergence of drug resistant viruses, requires that new 
molecules with different inhibitory mechanisms be investigated. These molecules include 
the lectins griffithsin (GRFT), cyanovirin-N (CV-N) and scytovirin (SVN) that bind 
mannose-rich glycans on gp120 (5, 32, 52). These compounds have been studied mainly 
against subtype B viruses although subtype C are the major cause of infections around the 
world. Therefore, this study involved an investigation into the ability of GRFT, CV-N 
and SVN to inhibit HIV-1 subtype C infection focusing on the array of mannose-rich 
glycans on the envelope glycoproteins. Since HIV-1 interaction with the DC-SIGN 
receptor on dendritic cells (DC) is very important for sexual transmission, I also 
examined GRFT, CV-N and SVN inhibition of HIV-1 binding to DC-SIGN. Lastly, 
given that HIV-1 has a propensity to evade antiviral compounds, the mechanism involved 
in its resistance to GRFT, CV-N and SVN was also studied.    
In Chapter Two, I show that despite their significant differences in mannose-rich 
glycosylation patterns, HIV-1 subtype C sensitivity to GRFT, CV-N and SVN is similar 
to subtype B (48). This study suggested that these lectins binding sites on HIV-1 are 
flexible. The importance of the 234 and 295 glycans in GRFT, CV-N and SVN binding to 
HIV-1 was also shown in this study. Nevertheless, it will be important to further 
investigate the role of specific glycans in the binding of these compounds. Such a study 
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will help determine the susceptibility of different circulating subtype C viruses to GRFT, 
CV-N and SVN. Lastly, given the high diversity of HIV-1 viruses (8), it is advisable to 
test these compounds against other subtypes such as D and F. The fact that these lectins 
inhibited subtypes C, B and A with comparable potency suggests that they may also be 
effective against other subtypes.  
Given that GRFT, CV-N and SVN are potential microbicides that will be applied 
in the female genital tract or in the rectum, for men who have sex with men, a study 
comparing the sensitivity of matched blood / genital or rectal canal viruses will be 
important. In Chapter Two, I showed that CAP63.A9J from blood and a matched 
envelope clone from CVL have similar sensitivity to GRFT, CV-N and SVN. However, 
further investigations with additional viruses from blood and genital or rectal canal needs 
to be conducted since compartmentalization has been shown to affect glycosylation 
patterns (22). Furthermore, semen contains cell associated and cell free viruses and the 
shedding of HIV-1 in this body fluid is a critical factor during the male to female 
transmission of the virus (9). Therefore, an important factor that should be considered in 
future research is that microbicides will mainly be used by HIV negative women and so 
the prime targets will be viruses that originate from semen of infected men. Thus, an 
investigation of the potency of candidate microbicides such as GRFT, CV-N and SVN 
against semen derived viruses would be important.  
 
In Chapter Three, I show that GRFT binding to gp120 exposes the CD4bs, 
therefore, making it more accessible to antibodies that target this epitope. This work has 
implications for HIV-1 vaccine research, given the importance of the CD4bs in the virus 
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life cycle and the fact that this site is highly conserved across HIV-1 subtypes (12, 23, 47, 
50). An important suggestion from this study is that GRFT, or compounds that mimic its 
action, could be used in combination with vaccines that elicit antibodies to the CD4bs. 
Similarly, there is a possibility of combining this lectin with CD4bs antibodies during 
passive immunization to prevent HIV-1 infection. In addition, GRFT and other mannose-
binding lectins have shown no toxicity to mammalian cells and Balzarini suggested that 
they or their smaller derivates could be used in vivo against HIV-1 (3). Thus, HIV-1 
infected individuals, many of whom have antibodies to the CD4bs (18), may be treated 
with GRFT to increase the virus vulnerability to these endogenous antibodies. This idea 
is supported by the fact that GRFT synergized with BB10 (Table 4 of Chapter Three), an 
HIV-positive plasma that contains CD4bs antibodies, to neutralize HIV-1.  
The inability of CV-N, which like GRFT has a symmetrical arrangement of 
carbohydrate-binding sites (52), to enhance HIV-1 binding to the CD4bs suggests that 
GRFT’s ability to expose this epitope has nothing to do with this geometric arrangement. 
Furthermore, GRFT belongs to the family of ß-prism-I lectins made of jacalin-related 
proteins (39). This family includes lectins such as jacalin (2), artocarpin (21) and heltuba 
(6). Thus, although GRFT shares less than 30% sequence identity with these other ß-
prism-I family members (51), it will be interesting to investigate whether they too share 
this ability to expose the CD4bs. Such a study will help in our understanding of GRFT’s 
ability to expose this conserved epitope.   
GRFT and b12 enhanced each others neutralization potency against HIV-1. A 
similar observation was made between GRFT and PRO140. These synergistic 
interactions have important implications for the use of this lectin as an HIV-1 
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microbicide since they suggest the possibility of using combinations of entry inhibitors in 
a single microbicide formulation. They also suggest that this lectin should be tested with 
other CD4bs antibodies such as VRC01, VRC02 and VRC03 as well as with other 
compounds that target HIV-1 co-receptors such as AMD3100 and maraviroc to determine 
whether there is synergism (14, 15, 40, 49). In brief, given the observations made in 
Chapter Three, it could be concluded that GRFT through its ability to bind glycans has a 
unique ability to synergize with compounds that target different sites on the virus or on 
susceptible cells and this warrants further investigations.  
 
Lectin receptors play the important role of mediating HIV-1 transfer to cells that 
are susceptible to infection at the sites of mucosal transmission (13, 41) and help 
disseminate the virus to the lymph nodes (35). The DC-SIGN receptor expressed on 
dendritic cells is one of the most important lectin receptors used by HIV-1 (36). Chapter 
Four shows that GRFT, CV-N and SVN are able to inhibit HIV-1 subtype B and C 
binding to DC-SIGN as well as the DC-SIGN-mediated transfer to target cells. The 
importance of this work stems from the fact that these three compounds are candidate 
microbicides and their primary site of application is the female genital tract that is rich 
with cells expressing the DC-SIGN receptor. Compared to the inhibition of transfer, 
GRFT, CV-N and SVN inhibition of HIV-1 binding to the DC-SIGN receptor was 
moderate. Thus, we postulate that the strong inhibition of HIV-1 transfer by these lectins 
is due to their potent inhibitory activities against the virus infection of cells, shown in 
Chapter Two. However, the relationship between lectin neutralization of free viral 
particles and their inhibition of DC-SIGN-mediated transfer is not a straight forward one 
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i.e. the ability of GRFT, CV-N and SVN to neutralize a given HIV-1 particle does not 
imply that they should also be able to inhibit DC-SIGN-mediated transfer. A plausible 
example is provided by CAP63.A9J and CAAN5342.A2 and their 234N mutants. In 
Chapter Two, the addition of the 234 glycosylation site markedly increased CAP63.A9J 
and CAAN5342.A2 neutralization sensitivity to GRFT, CV-N and SVN while in Chapter 
Four this mutation completely abolished lectin inhibition of the DC-SIGN-mediated 
transfer of these viruses. In Chapter Four, I also show that, at least in some viruses, the 
addition of the 234 glycosylation site increased HIV-1 interaction with the DC-SIGN 
receptor. This may explain why the presence of 234N affected lectin inhibition of HIV-1 
binding to DC-SIGN and transfer to target cells. Since the 234 glycan is conserved in ~ 
80% of subtype C viruses (48), its role in HIV-1 interaction with the DC-SIGN receptor 
needs further investigation.    
Like the DC-SIGN receptor, the mannose and the dendritic cell immune receptor 
(DCIR) are lectin receptors and have been shown to mediate HIV-1 infection of cells (10, 
24). More precisely, the mannose receptor was reported by Liu and colleagues to mediate 
HIV-1 infection in cis of astrocytes while the DCIR was shown by Lambert et al. to 
promote the infection in trans of CD4+ T cells (24, 29). Since, cells that express these 
receptors are also found in the cervico-vaginal tract (9, 25, 41), a study of the ability of 
GRFT, CV-N and SVN to inhibit the mannose receptor and the DCIR binding and 
transfer of HIV-1 to susceptible cells is needed. If these compounds are found to inhibit 
these interactions it would strengthen their case for further development as microbicides.  
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Previously, HIV-1 subtype B was shown to develop resistance to CV-N and other 
mannose binding lectins in vitro and the main mechanism of this resistance was the 
deletion of mannose-rich glycans (4, 20). Similarly, in Chapter Five, I show that subtype 
C viruses can become resistance to GRFT, CV-N and SVN via deletions of mannose-rich 
glycans. However, the fact that only Du179, out of the four viruses tested, tolerated 
concentrations of these lectins that were above five times their IC50 suggested that the 
generation of subtype C viruses that are resistant to these compounds may be difficult. 
This is supported by the observation that GRFT, CV-N and SVN resistant Du179 could 
still be inhibited with nanomolar concentrations of the lectins. The fact that glycans on 
HIV-1 envelope play important functional and structural roles (17, 26, 28-31, 44, 45) 
may explain why they cannot be readily deleted. This ultimately means that GRFT, CV-
N and SVN can be effective as HIV-1 subtype C microbicides since it may be difficult 
for the virus to escape their inhibitory activity.  
An important study that can be added to the one conducted in Chapter Five is the 
investigation of whether the deletion of mannose-rich glycans to escape GRFT, CV-N 
and SVN affects HIV-1 interaction with the DC-SIGN receptor. Given the promiscuity of 
this receptor in interacting with these glycans (19, 27, 31), one could speculate that 
loosing one or two mannose-rich glycans on the viral envelope may not affect DC-SIGN 
binding to HIV-1. However, the deletion of four or five glycans, as was observed with 
Du179 and Du151, has the potential to affect this binding. This study can also be 
performed with other lectin receptors such as the mannose receptor and DCIR.  
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Inevitably, there will be the question of what makes GRFT, CV-N and SVN better 
HIV-1 microbicide candidates than compounds that are already being researched for the 
same purpose; in particular tenofovir, the first microbicide candidate to show efficacy 
against HIV-1 in a human trial. As mentioned at the beginning of this Chapter, the main 
advantage GRFT, CV-N and SVN have over microbicide candidates such as tenofovir is 
that they are not used to treat HIV-1 infection and this removes the possibility that their 
topical use in infected individuals will generate drug resistant strains. Another advantage 
that lectins have over tenofovir is that they could also provide protection to a man 
engaging in sexual intercourse with an infected woman since the presence of these 
compounds in the vaginal tract could prevent infection of the male partner. Compared to 
other envelope inhibitors, especially those already in clinical trials (11, 37, 38), GRFT, 
CV-N and SVN are more potent with IC50 in the low nanomolar range across HIV-1 
subtypes (3, 5, 7, 34). CV-N was shown to protect macaques against SHIV89.6P while 
GRFT inhibited HIV-1 infection of human cervical explants (34, 42, 43). However, in 
humans, these lectins efficacy is likely to be affected by adherence. As shown in the 
CAPRISA 004 trial, poor adherence can lower the efficacy of microbicides against HIV-
1 infection (1). A possible solution to this is the use of vaginal rings containing the lectin, 
since once incorporated into the cervico-vaginal tract the ring will continuously release 
the microbicide over an extended period of time without the user’s intervention (33).  
Lastly, since GRFT, CV-N and SVN binding sites overlap on HIV-1 envelope, their 
combination in a single microbicide formulation is likely to result in competition for 
binding to the virus, thus, reducing their efficacy. The ideal way of using these lectins in 
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combination is, therefore, by using them with compounds that do not share the same 
binding sites on the HIV-1 envelope.   
 
The developing world, especially Sub-Saharan Africa, is the center of the global 
HIV-1 epidemic (http://www.unaids.org). Women in Sub-Saharan Africa are the most 
affected by the  virus and as already mentioned in Chapter One, this is due to their 
economic dependence on men, domestic violence, high incidence of rape and their 
inability to negotiate safe sex practices with their male partners (16). Thus, the 
availability of a female controlled microbicides is likely to result in a marked decrease in 
the rate HIV-1 transmission among women in this region and will lead to a significant 
decrease in the global epidemic. Note that a recent study found that an 80% use of the 
tenofovir gel could avert 2.33 million new infections and save 1.3 million lives in the 
next 20 years (46). Even a 25% adherence to this gel has the potential to save 0.29 
million lives, this study also found. Unlike in Sub-Saharan, in the developed world the 
sexual transmission of HIV-1 is mostly between men (http://www.unaids.org). However, 
since microbicides are also designed for application in the rectum they are likely to 
decrease the rate of infections in this part of the world as well.  
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